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Abstract 
 
Many active pharmaceutical ingredients (APIs) have poor physicochemical 
properties such as solubility, dissolution and chemical stability. Several 
strategies are used to enhance and improve these properties of the API.  Co-
crystallization and polymorphism studies are possible strategy used in pre-
formulation studies to optimize these properties of the drug without 
modifying its pharmacological effect. The purpose of this research was to 
investigate the polymorphism and co-crystallization effects of the penicillin-
type antibiotic, amoxicillin tri-hydrate. Several techniques such as: slow 
evaporation, slow cooling, vapour diffusion, sublimation, grinding and 
solvent assisted grinding was employed. In producing co-crystals, the API 
was non-covalently bound to selected co-formers such as: saccharin, 
nicotinamide, salicylic acid, L-tartaric acid, D-tartaric acid, L-aspartic acid, 
stearic acid, benzoic anhydride, oxalic acid di-hydrate, cinnamic acid, succinic 
acid and citric acid monohydrate. Nine co-crystals of amoxicillin tri-hydrate 
had been formed. Differential scanning calorimetry (DSC), hot stage 
microscopy (HSM) and thermal gravimetric analysis (TGA) was conducted to 
analyse the thermal behaviour of the co-crystals. Powder X-ray diffraction 
(PXRD) and spectroscopic techniques [infra-red (FTIR) and H1-nuclear 
magnetic resonance (H1MNR)] were employed for screening of the co-crystal 
forms. Furthermore, dissolution testing was conducted to investigate the 
application of the newly derivatised forms. 
Key words: - Amoxicillin-type antibiotics, co-crystallization, co-former, 
physicochemical properties, dissolution, X-ray diffraction. 
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CHAPTER 1 
INTRODUCTION
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CHAPTER 1: Presents a literature review of polymorphism and co-
crystallization and how these phenomena affect different physicochemical properties 
of a solid. The motivation for focusing primarily on amoxicillin tri-hydrate is also 
included. 
 
1.1 Solid state properties of drugs. 
Gases, liquids and solids are the three states of matter.1 In the solid state, the molecules, 
atoms and ions are bound closely together via intermolecular, intramolecular or ionic 
forces.1 There are two types of solids; the crystalline solid and the amorphous solid. 
Crystalline solids such as sodium chloride and ice are characterized by a fixed geometric 
shape, an orderly arrangement of the units (the units that form the crystalline structure 
can be atoms, molecules or ions) and they have sharp melting points.1 In contrast, 
amorphous solids like beeswax, paraffin and glass are arranged in a random manner and 
they do not have sharp melting points.1 Active pharmaceutical ingredients (APIs) can 
be present in a variety of solid forms.2 For example, salts, solvates (including hydrates), 
polymorphs, amorphs and co-crystals.2 Figure 1.1 illustrates the different solid forms of 
substances.2 
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   Figure 1.1: Different solid forms of substances.2 
 
The properties of solid substances such as particle size, shape and surface properties 
have significant effects on the formulation and production process of drugs.3 These 
properties of the solids are acquired and affected by the arrangement of the molecules 
within the structure of the solid.4,5 Any changes and/or interaction between these 
molecules can highly influence the properties of the solids, for instance solubility, 
hardness, density, chemical stability and physical stability.4,5 (Table 1.1) defines some 
of the physical properties relevant to this study.  
 
Table 1.1: Definitions of physical properties of a solid. 
 
 
 
 
 
 
Property  Definition 
Solubility The ability of the drug substances to dissolve in a given amount of 
solvent. 
Dissolution A dynamic process by which the amount of drug substances goes into 
solution per unit time under consistent conditions. 6 
Stability The ability of a drug substance or drug product to stay within 
established specifications to maintain its identity, strength, quality, and 
purity throughout the retest or expiration dating periods.7  
Bioavailability The rate and extent to which the active ingredient or active moiety is 
absorbed from a drug product and becomes available at the site of 
action.8  
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Poor dissolution rate, solubility and chemical stability has a profound effect on the 
therapeutic efficacy of many pharmaceutical ingredients.9 Whereas most of the drugs 
are formulated and administered as solid dosage forms such as tablets and capsules, 
chemial scientists employ different approaches in an attempt to modify the properties of 
the solids (to achieve a specific physicochemical property of the solid).4 Salts, 
polymorphs, co-crystals, hydrates and solvate formation are some of the strategies used 
to alter and modify the physical and chemical properties of the solid material.4 
Bonding forces between the molecules. 
Knowledge and understanding of the forces that bind the molecules of the             
substances are very important in the study of pharmaceutical structures.10 When the 
molecules exist in aggregates in the three states of matter (gases, liquids and solids), 
intermolecular forces must exist.10 The attractive forces are the forces that are essential 
for the molecules of the compound to cohere; repulsive forces are necessary for 
molecules not to interpenetrate and suppress one another.10 The following are brief 
descriptions of the different types of forces that hold the molecules together. 
 
 
 Van der Waals forces 
 
In this type of binding, dipolar molecules have a tendency to align themselves with 
their neighbour molecules. So, the negative part of one molecule points toward the 
positive part of the next molecule.10 
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 Ion-dipole-induced dipole forces 
 
Attraction between charged and polar molecules is involved in ion-dipole forces. This 
type of interaction is very important for the solubility of an ionic substance in polar 
solvents.11 
 Hydrogen bonds 
 
Hydrogen bonds are relatively weak bonds.10 There is no universal definition of 
hydrogen bonding however some definitions are based on a single operational criterion; 
others depend on a listing of suitable functional groups.12 It can be described as an 
attractive interaction occurring between a molecule containing a hydrogen atom on an 
electronegative atom and an electronegative atom or group of atoms in a different 
molecule or within the same molecule.13 Figure 1.2 shows hydrogen bonding formed 
within four molecules of water.  
 
H
O
HH
H
O H
O
H
H
O
H
OH H
 
 
Figure 1.2: Hydrogen bonding in water. (The dotted lines (….) illustrate the 
formation of the hydrogen bond. 
 
Two kinds of hydrogen bonds can be recognized: an intramolecular and an 
intermolecular hydrogen bond.12 Intramolecular hydrogen bonds are the bonds that are 
made between groups within a single molecule.12 Intermolecular hydrogen bonds are 
the association of two molecules of the same or different substances.12 It is very 
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important to mention that several physical and some chemical properties vary due to 
hydrogen bond formation in a compound or solution.12 These physical property 
modifications are commonly observed as a change in boiling point or freezing point and 
shifts of infra-red (IR) and Raman bands.12 Hydrogen bonding represents the most 
reliable anisotropic interaction in supramolecular recognition and crystal engineering.14 
An anisotropic interaction is the interaction that describe the situations where 
properties vary systematically, dependent on direction. By means of crystallographic 
data from single X-ray diffraction (SXRD), the presence of a hydrogen bond can be 
indicated.14 However a precise determination of a hydrogen atom cannot always be 
accurately determined.14 This requires neutron diffraction data for which the large 
neutron scattering power of the hydrogen atom nuclei means that it can be located with 
the same accuracy as many heavier atoms.  
 
1.2 Polymorphism  
 
 Introduction  
A large number of pharmaceutical ingredients can exist in more than one form and   the    
molecular packing pattern of each form in the crystal lattice are different.15 The   
difference may either be in the crystal lattice packing or in the orientation of the 
molecules in the lattice sites.16 This condition is called polymorphism. Polymorphism is 
common with pharmaceutical compounds and many drugs exhibit polymorphic 
behaviour.15 Some classes of drugs possess a high incidence of polymorphism, for 
example, barbiturates, steroids and sulphonamides.15 Four polymorphs have been 
identified for testosterone, whereas 65% of the commercial sulphonamides are found to 
exist in more than one polymorphic form.15 
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Each pharmaceutical polymorph of the same chemical compound has different chemical 
and physical properties. For instance, melting point, dissolution, solubility, stability and 
mechanical properties.16 Table 1.2 describes the physical properties that may differ 
amongst various polymorphs.16 
Table 1.2: Physical properties that may differ amongst various polymorphs. 
Physical properties 
1. Packing properties 
Molar volume and density, refractive index, conductivity, hygroscopicity. 
     2. Thermodynamic properties: 
Melting and sublimation temperatures, internal energy, heat capacity, 
entropy, vapour pressure, solubility. 
3. Spectroscopic properties: 
Electronic transitions, vibrational transitions, rotational transitions, 
nuclear spin transitions 
4. Kinetic properties: 
Dissolution rate, rates of solid state reactions, stability. 
5. Surface properties: 
Surface free energy, interfacial tensions, habit. 
6. Mechanical properties: 
Hardness, tensile strength, compatibility, tableting, handling, flow and 
blending. 
    
 Generally, one polymorphic form of the drug is stable and the other forms convert to 
the  stable form at different rates.17 The unstable form is called the metastable form.17 
The transformation to the stable form result from high thermodynamic activity (higher 
Gibbs energy).17 From a solubility perspective, in pharmaceutical preparations, the 
metastable form is usually preferred to be incorporated compared to the stable form 
since it has a higher solubility.18 Different polymorphs do not have a special 
nomenclature, they are mostly described by numbers using roman numerals I, II, III, 
etc. or α, β, γ etc.18 The numbering system preferred is usually based on the order of 
stability. For example, form I is the most stable form at ambient temperature.18 The 
most important effect of polymorphism is its effect on solubility. The solubility has a 
great impact on the dissolution process which has a further effect on the availability of 
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the drug in the body. If the solubility increases the dissolution rate increases.19 
Commonly, there is an important relationship associated with the solubility and the 
melting point of the different polymorphs.17 The most stable form has a strong lattice 
(it is difficult to remove a molecule from this compound) since it has a high melting 
point, therefore it exhibits a low dissolution rate.17 The other form may have a low 
melting point, the breakdown of the molecule is easier and it indicates a  higher 
dissolution rate.17 
 Historical overview 
From the middle of the 19th century, it had been recognized that many substances could 
be obtained in more than one crystalline form.20 In 1821 Mischerlich (a leading 
crystallographer) discovered two different forms of the NaH2PO4·H2O salt.10 That was 
the first recognition of the polymorphism phenomena. In 1832, polymorphism 
occurrences were discovered in an organic compound, benzamide.10 Within the same 
period, the principle of conversion of one polymorph to another was suggested by 
Frankenheim in1839.21 In 1897, on the basis of thermodynamics Ostwald concentrated 
on the stabilities of polymorphs, and suggested that the first solid formed on 
crystallization of solution or melt would be the least stable polymorph. 22 Using X-ray 
crystallography, Tammann regarded polymorphs as identical molecular species 
arranged on different lattices.23 
Preparation and characterization of polymorphs 
The preparation and characterization of polymorphs are very important in the 
pharmaceutical industry. There are numerous methods to prepare different polymorphs 
including, sublimation,24 crystallization from the melt, crystallization from supercritical 
fluids and crystallization from solution using different solvents and different 
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temperatures.18 Other commonly used methods involves slow cooling of hot saturated 
solutions,25 vapour diffusion, thermal treatment and grinding.24 
In general, the slow evaporation method is the easiest technique for crystallization of 
compounds. The crystal growth via this technique is highly influenced by the solvent 
choice.24 After a polymorph generation, a single or multiple analyses should be carried 
out to characterize the properties of the new solid formed.24  
Characterization of polymorphs 
Various analytical techniques have been applied to describe polymorphs. Generally, 
crystallography, microscopy, vibrational spectroscopy, thermal analysis and nuclear 
magnetic resonance are the most powerful for characterization of polymorphs.26 
Determination of the physical characteristics of a polymorph is usually the first step to 
describe the polymorph. Physical morphology of the generated polymorph is usually 
described using hot stage microscopy (HSM). HSM can provide complimentary 
information on phase transition.27 For the melting point determination, hot stage 
microscopy or differential scanning calorimetry (DSC) can be used. DSC is one of the 
most important types of thermal analysis techniques utilized for polymorph 
characterization.10 In this method of analysis, the samples are subjected to different 
temperatures, these temperature changes produce a number of physical and chemical 
effects.10 Characterization of these effects that happen to the samples upon heating and 
cooling is called thermal analysis.10 Thermal analysis using DSC involve two main 
process, heating of the material  sample under a controlled condition and observing any 
chemical and physical changes that may happen.10 Further structure information 
require both the powder X-ray diffractometer (PXRD) and single X-ray diffractometer 
(SXRD). X-ray diffraction can provide information about chemical composition, 
chemical structure and physical properties of materials and an in depth understanding 
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of the structure. SXRD is the ultimate technique where any difference in the packing 
arrangement and the confirmation of the molecules can be detected.25 Other techniques 
such as infrared (IR) spectroscopy and nuclear magnetic resonance (NMR) can provide 
further characterization of the crystalline material produced.24 After clear polymorphic 
identification of the compound various analytical techniques should be used in order to 
determine the properties of each polymorph to compare their properties to each other.
  
Types of polymorph 
Depending on the stability of polymorphs at different ranges of temperature and 
pressure, two types of polymorphs are recognized, monotropes and enantiotropes.16 In 
an enantiotropic system, one polymorph is stable (i.e. it has a lower free energy and 
solubility over a certain range of temperature and pressure) and the other polymorph 
has a higher free energy and solubility at different temperature ranges.16 A reversible 
transition at a definite transition temperature can be observed in an enantiotropic 
system.16 Acetazolamide, carbamazepine and metoclopramide are examples of 
enantiotropes.28,29,30 In contract, when one polymorph is stable at all temperatures and 
other polymorphs are unstable, the system is said to be monotropic.16  In this system no 
reversible transition can be observed below melting point.16 An example of this system 
include chloramphenicol palmitate and metolazone.28,29,30 
 
For stability treatment, the most common thermodynamic relationship is G = H – TS, 
where G = Gibbs free energy, H = enthalpy, T = absolute temperature and S = 
entropy.16 Figure 1.3 shows the variation of G and H at constant pressure against the 
temperature for two polymorphic systems. 
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Figure 1.3: A plot of Gibbs free energy and enthalpy (H) verses temperature (T)    
for (a) an enantiotropic system and (b) a monotropic system.16 
 
 
To recognize whether the polymorphs are monotropes or enantiotropes, Burger and 
Ramberger developed four thermodynamic rules.29 The heat of transition and heat of 
fusion rules suggested by Burger and Ramberger are the most applicable 
thermodynamic rules.16 For the heat of fusion rule, the two polymorphic forms are 
called enantiotropes, if the endothermic polymorphic transition is observed. 
Whereas, when the exothermic polymorphic transition is detected, then the two 
forms are monotropes.16 The heat of fusion rules explained that if the higher melting 
polymorph has the higher heat of fusion, the two forms are monotropes.16 On the 
other hand when the higher melting polymorph has the lowest heat of fusion, the 
two forms are enantiotropes.16 Other rules were found by Burger and Ramberger 
such as density and infrared rules which are less reliable compared to the heat of 
transition and heat of fusion rules.29 
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Stability and bioavailability of polymorphs 
Polymorphism involves diversity in the crystal structure of the compounds. So, 
different polymorphs of the same compound will have different energy contents. 
Whereas the arrangements of the molecules are different in each polymorph, the 
energy difference is largely concerned with the forces between these molecules in the 
structure.16 Throughout the manufacturing and storage process, the transformation 
of one polymorphic form to another may be occurring,31 especially when the 
metastable form is used initially.1 Many manufacturing processes have a potential 
effect on the polymorphic form of the drugs. It can produce a phase change of drug 
substances.26 For example, interconversions between anhydrates and hydrates is 
usually possible during the wet granulation process. It has been shown that the 
formation of an amorphous substance could result from a  spray drying process.32 
Certain polymorphs of some drugs have a different chemical stability such as 
indomethacin,33 furosemide34 and carbamazepine.35 Commonly, the polymorph that 
has a high thermodynamic stability is the more chemically stable polymorph 
compared to the metastable form.31 This is usually referred to the higher crystal 
packing density of the thermodynamic stable polymorph as well as the orientation of 
the molecules and the hydrogen and non-hydrogen bonding.31 The chemical 
reactivity difference between two polymorphs of the same compound could  result 
from a small change in the crystal packing. 32 Indomethacin is a typical example, 
which shows conformational polymorphism.33 It has two polymorphic forms; an α-
form (which is the metastable one with a higher solubility) and a γ-form (the 
thermodynamic stable form) and the density of the α-form is higher than that of the 
γ-form, thus suggesting the tighter packing of the less stable polymorph.33 The 
difference in crystal packing/hydrogen bond cause the lack of correlation between 
 
 
 
 
 12 
 
higher packing density and lower reactivity.33 Figure 1.4 33 illustrates that the α-
form has a higher density because of the  presence of one extra hydrogen bond.33   
      
(a) α-indomethacin (metastable)  (b) γ-indomethacin (stable form). 
 
 
 
(a) α-indomethacin (metastable)  (b) γ-indomethacin (stable form). 
Figure: 1.4: α and γ-forms of indomethacin along the a-axis. 36 
 
 
Polymorphism has a potential effect on the biological activity of drugs. As a result of 
solubility differences between the polymorphs of the same compound, the dissolution 
rate and the biological activity could show a significant difference as well.10 A research 
study conducted by Khalil et al. demonstrated that the polymorphic form II of 
sulfameter (antibacterial agent) was more active via oral administration than 
polymorphic form III.37 
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Kinetics of polymorphism 
While the thermodynamic factor is concerned with the stability of polymorphs, the 
kinetic factors are concerned with the polymorphic form determination.25 It‟s very 
important to study the structural aspects of the molecular assembly processes that lead 
to crystallization.25 The crystallization from a solution using different solvents and 
different temperatures are usually the techniques used for the production of different 
polymorphs.16 The unstable form is usually formed first during crystallization and is 
subsequently transformed to the stable form. This was reported by Gay Lussac during 
the 20th century.38 Ostwald, later presented a thermodynamic explanation for this 
phenomena and created the Ostwald step rule.38, 39,40,41,42 Ostwald´s rule stated that the 
most stable state with the lowest amount of free energy is not formed first, but the least 
stable state lying close in the free energy to the original state is formed first.38 The 
kinetics of the crystallization involves two major steps: nucleation and crystal growth.25 
The nucleation process is the first step, where a nuclei (small crystallites) is formed in 
the supersaturated phase.25 This step is  critical for the production of different 
polymorphs. 16 The second step, crystal growth, represents the main step in the 
crystallization process where the atoms or molecules in this stage displays a 
characteristic arrangement and is packed typically in a fixed position in space relative to 
each other.  These two steps determine the nature of polymorphs. 
 
Polymorphism in pharmaceutical formulations 
 
In the pharmaceutical industry, most of the drug substances are handled in powder 
form. Understanding the crystal properties as well as the solid state properties which 
include polymorphism, amorphism and solvate (hydrate), are very important in drug 
manufacturing.18 In pharmaceutical manufacturing and production, the development of 
the more dynamically stable polymorph is necessary to assure the bioavailability of the 
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drug product under the various storage conditions.43 Sometimes, metastable crystalline 
and amorphous forms are preferred to be developed.43 For example, in the situation 
where the faster dissolution or higher concentrations are required.43 During 
manufacturing and storage of the drugs, monitoring and assessment of the polymorphic 
alteration is very important.44 Sometimes the polymorphic conversion takes a long time 
or happens upon exposure to moisture and humidity.44 As different polymorphs have 
different physical, chemical and mechanical properties, careful consideration must be 
taken during the selection of the  polymorph for each dosage form.18 Inappropriate 
selection of the polymorphs may lead to problems during dosage form manufacturing. 
For example, in a suspension, choosing the wrong polymorph can cause a phase 
transition from the metastable form to the stable form and may lead to caking and 
crystal growth.18 A phase conversion can also happen when the incorrect polymorph is 
suspended in a cream base, where the stable, less soluble form will result in crystal 
growth. This will give an unacceptable gritty product.18 One of the most common 
suppository bases is cocoa butter (theobroma oil). This base is a polymorphic compound 
and tends to change to the metastable form when it is overheated. Therefore the 
finished product will melt at 25-30 °C which is not suitable or unusable.45 Furthermore, 
preparation of suppositories via the fusion method using this type of polymorphic base 
can be very difficult.46  
 Control of polymorphism 
Since polymorphs have different solubility, stability and other differences which can 
affect the efficacy of drug, control of polymorph considered is very important in the 
pharmaceutical industry. In an attempt to achieve a good quality product and a good 
performance of the drug product, adequate understanding of drug polymorphism as 
well as controlling the product formulation, development and manufacturing process is 
essential.47 Drug performance testing such as the dissolution test can be employed to 
 
 
 
 
 15 
 
assess the polymorphic change especially for poorly soluble drugs. 47 In very few cases, 
a solid state characterization of the drug product would have to be conducted. 47 Control 
of polymorph formation may be achieved by understanding the thermodynamic system 
of the polymorph (i.e. in form of energy verses temperature diagram) to prevent 
polymorphic transformation upon storage.18  
1.3 Co-crystallization  
Co-crystallization is one of the most important strategies used to optimize the solid 
state properties of drugs without modifying its pharmacological activity. Additionally, 
pharmaceutical co-crystals may enhance a variety of essential parameters such as 
compressibility, hygroscopicity and flowability.48 Co-crystallization provide good 
opportunities to produce and design new solid forms in the pharmaceutical area.9 
Furthermore, co-crystallization discovery of API increases the intellectual property 
protection of a particular drug product.49 The main advantage of co-crystallization is 
that any API could possibly form a co-crystal regardless of acidic/basic or ionisable 
groups.4 Many pharmaceutical co-crystals have been discovered of different drugs such 
as aspirin, ibuprofen and acetaminophen,50,51 Figure 1.5 shows the formation of a typical 
co-crystal between ibuprofen and nicotinamide.52 
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Figure 1.5: Acid-amide bonding in Ibuprofen-nicotinamide co-crystal 
 
 
Pharmaceutical co-crystals 
 
Pharmaceutical co-crystals are non-ionic supramolecular complexes.9 It‟s a unique 
multi-component crystalline solid,24 which contains a mixture of an API and a  
pharmaceutically acceptable co-crystal former [generally regarded as safe (GRAS)].9 
Co-crystal formation is considered as a tool to modify and optimize significant 
physicochemical properties of APIs. For instance; dissolution rate, stability, solubility, 
bioavailability and moisture uptake.4 A universal and typical definition of what a co-
crystal is, is still unavailable.4 Various academic literature apply different parameters to 
define co-crystals. Table 1.3 shows the different co-crystal definitions.4 
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    Table: 1.3: Different co-crystal definitions.  
Author                      Co-crystal definitions References 
Stahly, G. P.  “A molecular complex that contains two or more 
different molecules in the same crystal lattice”  
 
24 
Bhogala B.R. and 
Nangia, A.  
 
“Multi-component solid-state assembly of two or more 
compounds held together by any type or a combination 
of intermolecular interactions”. 
 
53 
Childs, S. L. and 
Hardcastte K.L. 
 
“Crystalline material made up of two or more  
components, usually in a stoichiometric ratio, each 
component being an atom, ionic compound or 
molecule” 
 
54 
Aakeroy, C. and 
Salmon D.J. 
 
 
“Compounds constructed from discrete neutral 
molecular species. All solids containing ions, including 
complex transition-metal ions, are excluded.” “Made 
from reactants that are solids at ambient conditions.” 
“Structurally homogeneous crystalline material that 
contains two or more neutral building blocks that are 
present in definite stoichiometric amounts.” 
 
55 
B.Bond, A. “Synonym for multi-component molecular crystal”        56 
Jones, W., 
Motherwell W.D. 
and Trask A.V 
 
“A crystalline complex of two or more neutral 
molecular constituents bound together in the crystal 
lattice through non-covalent interactions, often 
including hydrogen bonding.” 
 
57 
 
 
Vishweshwar P., 
McMahon J.A., Bis 
J.A. and 
Zaworotko, M.J. 
 
“Are formed between a molecular or ionic API and a 
co-crystal former that is a solid under ambient 
conditions.”  
 
51 
 
 
Commonly, co-crystals are solids at room temperature. They possess different 
properties, crystal structure and have different intermolecular packing arrangements 
compared to the individual components. With these differences co-crystals exhibit 
different physical properties compared to the pure components.9  
Crystal engineering and the design of pharmaceutical co-crystals 
 
 In 1955 the concept of crystal engineering was firstly established and introduced by  
Pepinsky.58 Subsequently crystal engineering was defined by Desiraju as "the 
understanding of intermolecular interaction in the context of crystal packing and in the 
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utilization of understanding the design of new solids with desired physical and chemical 
properties.59 
             Many publications and reviews regarding crystal engineering are available.51 In 
general, crystal engineering represent the way to design and grow crystalline 
molecular solids with the aim of certain desired and specific properties.60 Carboxylic 
acid moieties are one of the most commonly studied functional groups in crystal 
engineering.61 The functional groups within the carboxylic acids are self-
complementary and have an ability to form supramolecular homosynthons (by means of 
its complementary hydrogen bond donor and acceptor).62 Furthermore, a 
supramolecular heterosynthon can be formed via interaction with other functional 
groups such as amides.62 Figure 1.6 illustrates examples of supramolecular 
homosynthons and heterosynthons.63 A supramolecular synthon is a term presented by 
Desiraju64 and it describes the synthetic organic structural features of a supramolecular 
complex.62 
 
 
 
Figure 1.6: Example of (I) homosynthon and (II) heterosynthon. 
(I) Pyrimidin-2-amine-pyrimidin-2-amine supramolecular homosynthon. 
(II) Pyrimidin-2-amine-carboxylic acid supramolecular heterosynthon. 
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Co-crystal preparation  
There are two basic methods for co-crystal synthesis. The solvent based methods and 
the solid based methods. The solvent based methods include slow evaporation from a 
solution slurry containing the co-crystal formers mixed in a stoichiometric ratio. 18 The 
solid based methods include dry grinding, solvent assisted grinding and growth from 
the melt.51 For co-crystal formation, the design strategies are still being researched and 
the mechanism of co-crystal formation is far from being understood.65 A full 
understanding of the supramolecular chemistry of the functional groups within the  
given molecules is a requirement for a co-crystal design.51 It assists the selection of 
appropriate co-crystal formers, however when the molecule contains  multiple 
functional groups, the hierarchy of the possible supramolecular synthon is not easily 
addressed.51 In addition, the role of the solvent in the nucleation of co-crystals can be 
critical in achieving a specific co-crystal from solution.51 In the  co-crystallization 
process, there are different variables that affect the ability of an API to form a co-
crystal, such as types of co-former, the ratio of API : co-former, pressure, temperature, 
solvents and the method of crystallization.9  In chapter 2 of the thesis we describe more 
detail regarding co-crystal preparation. 
 
Characterization of co-crystals         
Several characterization techniques are used to describe both the structure and the  
physical  properties of co-crystals. For structure elucidation, infrared spectroscopy (IR), 
single X-ray (SXRD) and powder X-ray (PXRD) diffraction can be applied.14,66 For 
melting point determination, the differential scanning calorimeter (DSC), 
thermogravimetry analyser (TG) and hot stage microscopy (HSM) are used to 
determine the physical properties of the co-crystals.66,67 Scanning electron microscope 
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(SEM) can be used to determine the surface properties of supramolecular complexes. 
Other spectroscopic techniques such as Raman and solid state nuclear magnetic 
resonance (NMR) spectroscopy are utilized for new co-crystalline material 
characterization.68,69 Infrared spectroscopy is a very useful method to detect co-crystal 
formation, especially when the co-former used is carboxylic acid or when the neutral 
OH•••N hydrogen bond is made between an acid and base. From IR spectra, a diverse 
difference can be detected between a neutral carboxylic acid moiety and a carboxylic 
anion.4,55 For molecular structure determination, utilizing an IR pattern in combination 
with other spectral data is preferred.70 Generally, Raman spectroscopy is favoured over 
IR spectroscopy for rapidly checking of co-crystal formation.7271,72 Single X-ray 
diffraction is the most powerful analytical procedure for the determination of new 
crystalline material. However,  a suitable X-ray quality of single crystal cannot always 
be obtained4 and for this reason, performing a variety of solid state and spectroscopic 
techniques is much more useful to characterize new co-crystalline substances.72 
Analytical procedures are mentioned and explained in chapter 2. 
 
 
 Applications of co-crystals  
 
The co-crystallization process has a number of benefits. Co-crystallization has a 
profound effect on the physical properties of pharmaceutical ingredients like solubility, 
dissolution and bioavailability.18 In the pharmaceutical industry, co-crystallization 
techniques are considered as an alternative process for drug discovery (creation of a 
novel molecule) and drug delivery (tailoring and optimizing the properties of the 
compounds).51, 73, 74, 75 The co-crystal is not only useful for formulation but also for 
isolation and purification of the API. Furthermore, when the homochiral co-crystal 
formers are involved in co-crystallization, the process might be used for separation of 
enantiomers.76, 77, 78, 79 
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Polymorphism of co-crystals 
Some co-crystals can be present in several polymorphic forms. Data on the 
polymorphism phenomena of co-crystals is still very limited,80 but lately, the  literature 
indicates an increase in the number of  co-crystal polymorphs, where 45 systems have 
been identified.81  For example, polymorphism of benzoic acid (HBz) and sodium 
benzoate (NaBz) co-crystals were reported80 and the co-crystal of carbamazepine with 
nicotinamide and saccharin.82 
 
 
Co-crystal verses salt: 
 
Salt formation is used to improve the physical properties of active materials for its 
solubility, stability and crystallinity. It is frequently chosen as an alternative to the free 
acid or base.9 Currently on the market, there are numerous medicines available and 
administered as the salt form. None of these medicines are available as a co-crystal 
form. Salt formation strategies may experience many disadvantages. Salt formation is 
limited to a component that has an ionizable group within its structure, where a proton 
transfers from the acidic to the basic part in the ionic state.83 Such transfer is not 
necessary to create a co-crystal. Sometimes salt formation is not possible and cannot be 
carried out.9 This may be due to the absence of ionizable sites in the compound or the 
lack of suitable solid properties in that compound.9 In such instances, co-crystal 
formation is a very good alternative method. It can be very difficult at times to 
distinguish between a salt and a co-crystal.84,85  A deep understanding of the main 
difference between the two (salt and co-crystal) is essential and critical in pre-
formulation and pharmaceutical developmental aspects.84,85 Salt or co-crystal formation 
between two individual components can be predicted.9 It depends on the pKa value of 
the acid and base. 9 For salt formation, at least 3 pKa unit differences between an acid 
and base are required. If this specific difference is not possible, a co-crystal will form.86 
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Recent research studies compared the reactivity of para-amino benzoic acid (PABA) and 
sulfamerazine (SMZ) with PABA and sulfamethazine (STH) using neat grinding and 
solvent-drop grinding.87 It was found that with 2.13 pKa unit difference, the PABA and 
SMZ was capable to form a binary eutectic, where with a larger pKa difference 2.59, the 
PABA and STH formed a co-crystal.87 This study shows the impact of the stereo-
hindrance which should be considered during the pharmaceutical co-crystal design.86 
 
Co-crystal verses solvate 
 
The solvate form of the substance is the form that contains a solvent molecule inside 
the crystal structure.16 In general, the physical state of isolated pure compounds specify 
whether the substance is in co-crystal or solvate form.9   If one component is a liquid at 
room temperature, the crystals are nominated as solvates and if the two components are 
solid at room temperature, the crystals are nominated as co-crystals. 
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Amorphous form 
An amorphous solid is the solid that lacks an ordered arrangement of the molecules and an 
obvious crystal lattice.88 It may be considered as supercooled liquids.10 This type of material 
has no clearly defined molecular structure and no long-range order.16 Furthermore, 
amorphous solids do not possess a definite molecular conformation, however they might 
hold short-range order.89,90 Even though crystalline solids have an advantage of chemical 
and thermodynamic stability, the amorphous solid is frequently preferred due to the desired 
pharmaceutical properties that amorphous solids have.91 For instance, novobiocin acid 
(antibiotic) has a crystalline and amorphous form. The crystalline form of this drug is 
poorly absorbed and not therapeutically active, while the amorphous form is readily 
absorbed and therapeutically active.91 One of the most important and critical physical 
properties is the dissolution of a drug substance.  Amorphous pharmaceuticals have an 
advantage of fast dissolution. The dissolution property usually affects the bioavailability of 
the drug.18 A high dissolution results in a high bioavailability. Amorphous solids have a 
tendency to recrystallize in an aqueous medium through a form of transition.92 The 
difficulty of avoiding this recrystallization during the dissolution, limits its use as a 
marketable dosage form in order to enhance its oral bioavailability.92 Several methods have 
been employed in an attempt to obtain amorphous solids of APIs, for example, quenching a 
melt by rapid cooling,93 reduction of particle size and removal of solvent from solvate or 
hydrate.18 Amorphous solids can also be obtained from the melts of compounds via a 
solidification process in such a way as to avoid the thermodynamic crystallization process 
and by disrupting an existing crystal structure.16  Causal observation is not continuously 
possible to determine whether the material is amorphous or crystalline.10 Some substances 
like beeswax appear to be amorphous, but when subjected to heating and then cooling, it 
assumes a crystalline arrangement.10 On the other hand, some materials contain both 
crystalline and amorphous constituents, for example, petrolatum. 10 
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1.4 Active pharmaceutical ingredients 
Introduction 
The active pharmaceutical ingredient examined in this study belongs to the β-lactam 
antibiotics. Antibiotics are specific chemical substances produced by micro-organisms 
and it has the ability to inhibit or kill other micro-organisms.15 This study focused 
specifically on the penicillin sub-class of antibiotics. Penicillins represent the main β-
lactam antibiotic family group. The antibiotic properties of penicillin were discovered 
by Fleming in 1929.94 Structurally, the β-lactam ring represents the basic nucleus of 
this group of antibiotics.95 In the penicillin group a 5-membered thiazolidine ring is 
fused to the β-lactam ring through a nitrogen and adjacent tetrahedral carbon atom.95 
 
 Mechanism of action 
 
β-lactam antibiotics produce their lethal effect only on growing bacterial cells.96 This 
type of antibiotic affects the bacterial cell wall. The bacterial cell wall is very important 
for bacterial growth and vitality.97 In the two bacteria species (Gram-negative and 
Gram-positive bacteria), the cell wall contains a cross linked polymer called the 
peptidoglycan.97 The peptidoglycan is the component that provides the mechanical 
stability of the bacteria.98 The structure of the cell wall is relatively different between 
the two of bacteria.99 In the Gram-positive bacteria, the bacterial cell wall is thicker 
compared to the Gram-negative bacterial cell wall.99 The lethal effect of  β-lactam 
antibiotics acts by binding to one or more penicillin binding proteins (PBPs) which is 
located within the cell wall of the bacteria and inhibits the  peptidoglycan synthesis.95 
Synthesis of peptidoglycan is stopped by inhibiting the final transpeptidation step, this 
stage is required for bacterial cell wall synthesis.95 The ability of β-lactam antibiotics to 
 
 
 
 
 25 
 
reach the PBP receptor and their stability against β-lactamase (enzyme produced by a 
special strain of bacteria responsible for β-lactame inactivation) are the factors that 
affect the activity of this compounds.100 Figure 1.7 shows the mode of action of β-lactam 
antibiotics.101 
 
Figure: 1.7: Mechanism of action of β-lactam antibiotics.101 
 
Amoxicillin tri-hydrate 
 
The study focused on amoxicillin tri-hydrate which is one of the broad spectrum 
penicillin‟s.  It is a semi-synthetic antimicrobial agent15 and has a high effect against 
gram-positive bacteria with a limited effect on gram-negative bacteria.102 Compared to 
ampicillin; amoxicillin has a greater activity against Strep. Faecalis and Salmonella spp., 
but is less active against Shigella spp.103  
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 Pharmacokinetics of amoxicillin tri-hydrate 
After oral administration the absorption of amoxicillin is rapid and higher compared to 
other β-lactam antibiotics.102 Amoxicillin is resistant to gastric acid and its absorption is 
not affected by the presence food.104 When it is given intramuscularly, the drug 
concentration reached is the same as the concentration achieved after oral 
administration.104 Amoxicillin has a slight ability to bind to plasma protein and only 
20% of the drug is bound to plasma protein.105 It is distributed widely in the body 
fluids.104 It appears low in concentration and safe in milk.106 It also crosses the 
placenta.106 The elimination of amoxicillin from the body takes place via renal 
elimination106 and upon metabolism it converts to the inactive penicilloic acid and then 
it is excreted in the urine.106 After oral administration about 60% of amoxicillin is 
excreted unchanged through glomerular filtration and tubular secretion mechanisms.105 
  
Physical and chemical aspects  
 
Chemically amoxicillin is an α-amino-p-hydroxybenzyl penicillin.107 Figure 1.8 shows 
the chemical structure of amoxicillin trihydrate.108 As with other penicillin drugs of 
antibiotics, it is characterized with a 6-aminopenicillanic acid structure. This is the basic 
and essential part of the structure‟s integrity.109 It consists of a thiazolidin ring attached 
to a β-lactam ring that carries a secondary amino group (RNH-).109 Stereochemistry 
shows three chiral carbon atoms present at C2, C5 and C7 in the penicillin structure.104 
Amoxicillin is an almost white powder with a slight sulphurous odour while amoxicillin 
tri-hydrate is an off white powder, slightly soluble in water and particularly insoluble in 
fatty acid,110 chloroform and ether.111  It dissolves in dilute acids and dilute solutions of 
alkali hydroxides.112 It has  pKa values  of 2.67, 7.11 and 9.55 at 37 °C.112  
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Figure 1.8: Chemical structure of amoxicillin tri-hydrate. 
 
Degradation of amoxicillin 
The reactivity of the strained β-lactam ring is responsible for amoxicillin degradation; 
especially hydrolysis.109 The nucleophilic attack at the β-lactam carbonyl group by 
water leads to the formation of an inactive compound named penicilloic acid.105 The 
penicilloic acid is stable in neutral and alkaline solutions. In acidic solutions, it 
undergoes decarboxylation and hydrolytic reactions.105 Reaction with metallic ions such 
as copper and zinc lead to amoxicillin inactivation. 109 In general, penicillins are also 
inactivated  by oxidizing agents, while reducing agents do not have a potential effect on 
this type of antibiotic.109 Amoxicillin is susceptible to degradation by β-lactamase 
producing bacteria.102 Many bacterial species produce this enzyme such as staphylococcus 
aureus and most of Gram-negative bacilli like, Escherichia coli.113  In an attempt to 
increase its spectrum against gram-negative bacteria, amoxicillin is combined with 
clavulanic acid (β-lactamase inhibitor). 
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Indication and therapeutic uses 
 
Amoxicillin is used in the treatment of many human and animal infections caused by 
gram-negative and gram-positive bacteria.114  It is used in the treatment of infections  
caused by β-lactamase negative strains of microorganisms, including the ear, (for 
example, otitis media) the nose, the throat, the skin and genito-urinary tract 
infections.102 Amoxicillin is also active in gonorrhoea and lower respiratory tract 
infections.102 Amoxicillin is used widely in combination as a mixture with clavulanic 
acid as a broad spectrum antibiotic. The combination is very useful in the treatment of 
different bacterial infections.105 The combination product is available in oral and 
injectable dosage forms.115 
1.5 Amoxicillin tri-hydrate co-crystal study - review 
Studies were conducted to investigate the physical aspects between amoxicillin tri-
hydrate and the salt of clavulanic acid (potassium clavulanate). The potassium salt 
instead of the free acid was used in these studies. 
A study by Nugrahani et al (2007) compared the antibiotic potency of amoxicillin-
potassium clavulanate co-crystal and the physical mixtures of the two compounds 
(amoxicillin tri-hydrate-potassiun clavulanate mixed in molar ratios: 0:10, 1:9, 2:8, 3:7, 
4:6,5:5, 6:4, 3:7, 8:2, 9:1, 10:0) against a non-β-lactam bacteria namely Sarcina Lutea 
sp.116  Potassium clavulanate is a salt and it is used in combination with amoxicillin tri-
hydrate. The research demonstrated that the antibiotic potency of the amoxicillin co-
crystal showed significant increase in potency at molar ratios 3:7 and 7:3 and at molar 
ratios 4:6, 6:4, 8:2 and 9:1. The co-crystal antibiotic profile was significantly different 
from the physical mixtures.116 Physical mixtures and co-crystals were analysed by 
differential scanning calorimetry (DSC) and the crystal structures were analysed by X-
ray powder diffractometry. Single X-ray diffraction to isolate the exact structures of the 
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crystals was not possible with the material prepared. The morphology of the physical 
mixtures and co-crystals were observed by scanning electron microscopy (SEM) 116 and 
the activity of the co-crystals were observed by measuring the inhibition116. It is noted 
that the authors did not consider using they were indeed using the salt of the co-former 
(potassium clavulanate) which disqualifies the study as a co-crystal study. 
Another study was conducted to evaluate the solid state interaction between 
amoxicillin tri-hydrate and potassium clavulanate. Here the assumption was made that 
a strong interaction via hydrogen bonding occurred between the hydrates of 
amoxicillin and potassium clavulanate.117 Again, the salt form of potassium clavulanate 
was used in the interaction and the product, even though defined as a co-crystal system, 
disqualifies as per the true definitions of a co-crystal (page 17).      
 
Amoxicillin tri-hydrate in various pH solutions - review 
The pH of the crystallization medium can produce different effects on drug 
properties.118 In a study by Shahhet et al (2011), amoxicillin tri-hydrate was 
recrystallized from aqueous solutions at different pH values (2, 4, 7, 9 and 11).118 
Recrystallization was conducted by preparing saturated aqueous solutions of 
amoxicillin tri-hydrate with different pH values, where 3 g of amoxicillin tri-hydrate 
was dissolved in a suitable amount of appropriate medium at 80 °C. After filtration of 
the solution, the filtrate was kept at 8o °C for 48 hours.118 After the 48 hours the 
precipitated crystals were filtered and spread out on a petri-dish to dry overnight and 
further dried in a vacuum oven.118 The result of the study showed that the dissolution 
rate of amoxicillin tri-hydrate is highly affected by the pH of the crystallization 
medium, crystal shape and the particle size.118 The study concluded that at pH 11 and 9 
the dissolution rate of the recrystallized  samples was higher than the samples 
recrystallized at pH 2, 4 and 7.118   
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1.6  Aim of the project 
 
The aim of this study was to investigate the co-crystallization and polymorphic effects 
of amoxicillin tri-hydrate. Amoxicillin tri-hydrate has proven to exhibit poor 
physicochemical properties such as solubility, dissolution and chemical stability. This 
study used several strategies to enhance and improve these properties of the API. The 
study of co-crystallization and polymorphism are possible strategies used in pre-
formulation to optimize these properties of the API without modifying the drugs 
pharmacological effect. Using various methods, different properties of newly prepared 
forms of the drug were investigated using several analytical techniques. The thermal 
behaviour of polymorphs and co-crystals produced was examined and characterized by 
DSC, TGA and HSM. Spectroscopic techniques such as FTIR and 1H-NMR were used, 
for co-crystal identification together with PXRD. The morphology of the co-crystal 
was obtained using an electron scanning microscope (SEM), while dissolution studies 
were achieved to compare all new forms synthesized with the pure amoxicillin tri-
hydrate.  
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CHAPTER 2: Presents the materials used in the study, its sources, a brief 
summary of its identification, all experiments, the different instruments used for the 
thermal and spectroscopic analysis of experiments, the dissolution evaluation and 
finally, the variables affecting the outcome of experiments. 
2.1 Materials 
The active pharmaceutical ingredient amoxicillin tri-hydrate, was obtained from Sigma-
Aldrich, UK. The twelve co-formers used in this study namely; saccharin, nicotinamide, 
salicylic acid, L-tartaric acid, D-tartaric acid, L-aspartic acid, stearic acid, benzoic 
anhydride, oxalic acid di-hydrate, cinnamic acid, succinic acid and citric acid 
monohydrate were supplied by Sigma-Aldrich, India. The different solvents used in the 
experiments, namely; methanol, ethanol 96%, propanol, benzyl alcohol, 1,4-dioxane, 
diethyl ether, chloroform, acetone, polyethylene glycol, toluene, ethyl acetate and 
dimethyl sulfoxide (DMSO) were obtained from Merck chemicals (PTY) LTD, 
Gauteng, South Africa. 
Other solvents used for co-crystal and polymorph preparation were prepared in the 
laboratory as follows: 
A. Sodium hydroxide (NaOH) 0.1 M 
4.0 gram of NaOH was weighed and dissolved in 600 ml of distilled water, then 
transferred to 1000 ml volumetric flask and made up to volume (1 L). 
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B. Hydrochloric acid (HCL) 0.1 N solution. 
0.1 N of HCL solution was prepared using 37% hydrochloric acid. A calculated amount 
of acid (9.8 mL) was added to 990.2 mL of water to obtain 1000 mL of 0.1 N HCL 
solution. 
37% HCl means 37 gram/100 ml 
whereas  HCl is a mono protonic acid, so the molarity = normality 
M=N= 37 gram /100 ml or 370 grams/litre 
             36.5 g/ mole (molar mass of HCL) 
Using N1V1=N2V2 
Where N2=0.1 N and  V2= 1000 ml 
    N1=370 g /36.5 g/mol           V1=? 
            N2=0.1 N                               V2=1000 ml 
             Calculate the volume required from the concentrated acid. 
             V1= N2V2/N1 
V1=9.8 ml, hence 9.8 ml from 37% HCL solution was made up to 1000 ml with    
water. 
 
C. Phosphate buffer at pH 5.8. 
 
Standard potassium phosphate, monobasic 0.2 M solution was prepared first. For the 
standard buffer solution preparation, a 1 M NaOH solution was required. It was 
prepared by dissolving a 2.0 gram of NaOH in 500 ml of distilled water. 6.805 gram of 
monobasic potassium phosphate (KH2PO4) was dissolved in 250 ml distilled water, then 
50 ml of this solution was transferred to a 200 ml volumetric flask and made up volume 
with the 0.2 M NaOH previously prepared.1 
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2.2 Compound identification 
All chemical substances used in this research were identified and characterized with 
several analytical techniques. The melting point determination of each compound was 
the first identification procedure. For this purpose, thermal analysis utilizing DSC was 
conducted. Fourier transform infra-red spectroscopy (IR) was also used for 
characterization and identification of compounds.2 From the IR spectra, information 
about the presence of the molecular structure could be obtained.3 The IR spectra of 
amoxicillin tri-hydrate and different co-formers were collected using a PerkinElmer 
Spectrum 400 FT-IR Spectrometer over the region of 400-4000. From the IR spectra, 
the identification of compounds used in the study were characterized by specific bands 
pertaining to its specific functional groups. Powder X-ray diffraction was also employed 
for identification purposes. The FTIR spectra, DSC thermogram and PXRD pattern of 
all compounds are attached in appendix A.   
2.3 Experimental methods 
2.3.1 Methods to prepare polymorphs 
 
Crystallization from a single solvent  
A known amount of the amoxicillin tri-hydrate was weighed and transferred into a 
clean vial. The selected solvent was added to the vial, the vial was fitted with a 
magnetic stirrer, placed on a hot plate and adjusted to a specific rotation. The 
temperatures of the hot plate were 10 °C below the boiling point of the solvent. Once a 
clear solution had formed, the solution was filtered using a PVDF® 0.45 µm pore filter 
into a clean, labelled vial and covered with parafilm®. For evaporation of the solution, 
small holes were made in the parafilm® using a needle. The solution was left 
undisturbed for a period of time to allow for evaporation of solvent to proceed and 
crystallization to occur.  
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Crystallization from a mixture of solvents 
The slow evaporation method using more than one solvent depends on the difference of 
the solubility of the compound in various solvents. In this technique two or more than 
two solvents are used, where the compound is soluble in one solvent and insoluble or 
sparingly soluble in the second solvent. The experiment was carried out in a vial on a 
hot plate. Different temperatures used in this experiment were 30 °C, 50 °C and 80 °C. 
After addition of the second solvent into the vials containing a solution of the 
compound with the first solvent, the final solution was filtered and the vials kept 
covered with perforated film and slow evaporation was allowed to take place.  
Vapour diffusion 
A solution of amoxicillin tri-hydrate prepared using a suitable solvent (S1) was placed 
in a clean, open small vial. The solution (S1) was then placed in a closed, wider 
container containing a volatile and miscible solvent (S2). The container was tightly 
closed. At the equilibrium, slow diffusion of S2 into the vial containing S1 occurred 
until saturation or super saturation was achieved. The containers were left for a period 
until crystal growth occurred. 
Grinding  
Polymorphic transformation can be achieved in the laboratory by neat manual grinding 
using a mortar and a pestle. A variety of solid state transformations like crystalline to 
amorphous,4 amorphous to crystalline5 and polymorphic transformations6 can be 
obtained by grinding. Many drugs such as barbital, sulfathiazole, indomethacin and 
chlorpropamide showed polymorphic transformation during the grinding process.7 
Byrn indicated that there are three main steps required for polymorphic transformation 
in the solid state. The first step is a molecular loosing (nucleation), the second step is a 
solid solution formation and finally, crystallization of the more stable product.8 
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Different drugs undergo such transformation under different conditions during the 
grinding procedure. For example, indomethacin transformed to a non-crystalline solid 
while grinding at 4 °C, whereas at 30 °C indomethacin converted to a metastable form 
A.7 For this study, the grinding was conducted by weighing a specific amount of the 
active ingredient (amoxicillin tri-hydrate) and grinding the material manually in a clean 
dry mortar for a specific period of time. The grinded material was kept in small vials for 
analysis. 
Solvent-drop grinding 
Grinding in the presence of several drops of a solvent is another method implemented 
to obtain polymorphs. A specific amount of the compound was grinded manually using 
a small mortar and pestle. A selected solvent was added drop wise during the grinding 
procedure. The grinding was carried out for a specific period of time. The grounded 
substance was transferred into a glass vial for further analysis. 
 
Recrystallization from the melt 
Cooling of polymorphic material can result in the production of the least stable 
modification which then can rearrange to the stable modification. A small amount of the 
substance was placed on a clean glass slide under the HSM, the temperature was 
adjusted to reach the melting point of the component, and then the melted ingredient 
was allowed to cool by decreasing the temperature below the melting point to check 
whether any new solid forms had occurred upon cooling. 
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2.3.2 Methods to prepare co-crystals 
 
Solvent evaporation method 
 
The slow evaporation method was employed by preparing a solution containing a 
stoichiometric amount of co-crystal formers using one solvent or mixtures of solvents. 
By means of a hot plate and a magnetic stirrer, each component was dissolved 
separately in the solvent until complete dissolution occurred. The two solutions were 
then added together and allowed to mix. The final solution was then filtered through a 
0.45 µm micro filter into a clean vial. The vial was closed with parafilm® and punctured 
to allow the solvent to evaporate. In this method temperatures were adjusted to 10 °C 
below the boiling point of the solvent. The solubility of the compounds played a very 
important role in the preparation of co-crystals from the solution. The compounds had 
to possess a similar solubility profile in each solvent. If one compound was less soluble 
than others, the precipitation of this compound would occur. However, similar 
solubility did not mean success of co-crystal formation. 9 
Grinding 
Pharmaceutical co-crystals can be formed by neat (dry) grinding. The co-crystal 
formers were mixed and ground together manually using a small porcelain mortar and 
pestle. The resultant product from the grinding exercise is usually consistent compared 
to the one produced from the solution.10,11 A few co-crystal materials can only be 
prepared by solid grinding, on the other hand, large number of materials can be 
prepared by both methods, from solution growth and grinding,10,12 for example 2:1 
caffeine/formic acid co-crystal.13 
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Solvent-drop grinding 
This technique is described as the addition of a small amount of the appropriate solvent 
to a mixture (the drug and the co-crystal former) by reducing the excessive use of the 
crystallization solvent.14 Furthermore the method has the advantages of cost-
effectiveness and reliability. It counts as a green method for exploring new co-crystals 
and also for preparation of obtainable co-crystals.15 It has been reported by Trask et al16 
that the dry state grinding of  cyclohexane-1,3-cis-5-cis-tricarboxylic acid and 4,4′-
bipyridine doesn‟t produce  a co-crystal, whereas grinding the same two components in 
the presence of methanol facilitates complete conversion in a short time.16 
Heating treatment 
A stoichiometric amount of amoxicillin tri-hydrate was mixed for a while with a specific 
amount of each co-former and the mixture of the two components was transferred into 
a porcelain crucible and heated over a hot plate at different temperatures (30, 50, 80 °C) 
for 30 minutes. The heated materials were then transferred to a clean vial for the 
purpose of analysis. 
2.4 Analytical methods employed 
 
 Multiple analytical techniques were employed to characterize and analyze the different 
forms of the API (amoxicillin tri-hydrate) produced. More detail of each technique is 
discussed below.  
 
Infrared spectroscopy  
 Fourier Transform Infrared (FTIR) was used for the purpose of compound 
identification (for either co-crystal or polymorph identification). All spectra were 
collected using a PerkinElmer Spectrum 400 FT-IR Spectrometer over the region of 
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400-4000 cm-1. The analysis of the spectra conducted used Spectrum software version 
6.3.5.  The IR spectra of the new compounds were compared to the parent compounds, 
where each molecule had a specific infra-red absorption pattern.17 
Hot stage microscopy 
 
Hot stage microscopy was conducted in an attempt to determine some properties of the 
new co-crystal or polymorph produced. The shape (physical appearance), melting point, 
possible phase transition and decomposition were the three main properties observed. A 
small amount of the sample was used. The samples were treated with silicon oil under 
the microscope. Using the silicon oil was important for solvent detection in the sample.  
In this study a Linkam TH MS600 Temperature control stage connected to a T95 
Linkpad System Controller was used. Heating of the products was controlled at a fixed 
rate (5 °C per minute). An Olympus SZX7 stereoscopic microscope was connected to an 
Olympus UC30 colour video camera and this was used to capture pictures for the 
determination of visual observation and characterization. The images were recorded 
and saved by Stream essential® software. 
Differential scanning calorimetry  
Differential scanning calorimetry (DSC) is one of the most important types of thermal 
analysis techniques. Thermal analysis using DSC involve two main process, heating of 
the material  (sample) under a controlled condition and observing any chemical and 
physical changes that may occur.18 Thermal analysis of the sample was conducted using 
a Perkin Elmer differential scanning calorimeter DSC7 connected to a Perkin Elmer 
thermal analysis controller TAC7/DX and Perkin Elmer thermal analysis gas station. 
The samples were scanned at a fixed heating rate (10 °C/min) under a N2 gas with a 
flow rate of 20 ml/min. Each weighed sample (mass rang  of 1.5-2.9 mg) was crimped in 
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an aluminium pan. The reference used was a sealed empty pan. The calibration of the 
DSC was performed by the melting point determination of indium (165 °C). The 
samples were heated over the range of 30-285 °C .The data was collected and analysed 
using Pyris software. The data collected from the DSC were confirmed with the HSM 
results. 
Thermal gravimetric analysis (TGA) 
Thermogravimetry (TG) is the technique used to detect the physical or chemical 
change of material. It measures the mass loss of the sample as a function of time or 
temperature. TG analysis of all compounds was employed using PerkinElmer 
thermogravimetric analyser TGA 4000 connected to Polyscience digital temperature 
controller under N2 gas flowing at a rate of 20 ml/minute. The sample was weighed in 
a porcelain crucible and analysed over the range of 30 -300 °C. The data was collected 
and analysed using Pyris software. 
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Nuclear magnetic resonance (H1-NMR) 
 NMR is one of the most powerful spectrometric techniques used for structure analysis 
of compounds. In this study, liquid state NMR was not used to elucidate the structure, 
since NMR would only be able to identify the presence of the two co-formers but not 
the non-covalent interaction between the two. Hence, liquid state NMR was used 
intentionally only after the DSC, HSM, FTIR and PXRD analysis to determine the 
ratio of the components and to verify homogenousity. Solid state NMR is superior for 
co-crystal characterization, which can access information of the chemical structure at 
molecular level. A small amount of the sample (5 mg) was weighed and dissolved in 
sufficient amount of deuterated dimethyl sulfoxide (DMSO-d6). The sample solution 
was transferred into NMR tubes. The tubes were imported from Sigma-Aldrich 
WILMAD®, USA. The spectra were recorded by Varian XR200 MHZ spectrometer. 
NMR analysis was conducted to check the homogenousity and to estimate the ratio of 
the components comprising the co-crystal. All NMR spectra are found in Appendices at 
the end of this dissertation. It is noted that the quality of the spectra was not of a high 
standard for the pure compounds analysed even after several repeated attempts. The 
reason for the poor quality of the data is attributed to the age and poor sensitivity of the 
NMR machine. The data however is still included since we not only relied on NMR but 
other analytical data were used as well to conclude the homogenousity and ratio of co-
crystal formation. The purity of the co-crystal formed was further confirmed by DSC 
and PXRD. 
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Powder X-ray diffraction 
X-ray crystallography techniques are concerned only with the structure analysis. It is 
considered as the most powerful tool for polymorphic identity specification. A 
prepared sample in the solid state was manually packed into capillaries with an 
internal diameter of 1 mm and wall thickness of 0.01 mm. The pattern of the sample 
was recorded using a Nickel-filtered CuKα radiation (λ= 1.5418 A°), produced at 48 
kV and 30 mA by a Philips PW1120/00 generator fitted with a Huber long fine-focus 
tube PW2273/20 and a Huber Guinier MonochromatorSeries 611/15. 
 
Electron scanning microscope (SEM) 
SEM is the technique that provides a high resolution imaging of the surface of particles. 
In this type of microscope, a beam of electrons generated by a thermal emission source 
is focused on the sample. When the electron interacts with the atoms of the material, 
various signals are released that provide information regarding the sample morphology 
and composition. All sample images were captured with a Uriga Cobra microscope and 
secondary electron images were recorded at an accelerating voltage of 5 keV using an 
in-lens secondary electron detector.  
Dissolution testing 
Dissolution studies were conducted using the rotating basket method according to the 
US Pharmacopeia volume 36. The test was conducted by the South African Bureau of 
Standards (SABS) Company, South Africa. Gelatin capsules were filled with 10 mg of 
the sample formulation, the powder particle size range was between 60-200 μm. Water 
at a temperature of 37 °C (pH 7) was used as a dissolution medium where 900 ml filled 
the dissolution vessels. A stirring speed of 100 rpm was applied. The dissolution was 
conducted using a validated SOTAX Smart System fitted with seven vessels, six for the 
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samples and the seventh to store the replacement medium at the correct temperature. 
Baskets (Apparatus 1) as per USP standards were used.   A calibrated Agilent 
8453 UV/Vis spectrophotometer was used to read the absorbance sample solutions at a 
wavelength of 272 nm. 
 
2.6 Variables affecting amoxicillin tri-hydrate co-crystallization. 
Solubility and stability 
 For co-crystal formation, the two components (API and co-former) must possess 
the same solubility in the same solvent, if not, the less soluble compound will 
precipitate.10 In this study, amoxicillin tri-hydrate has a poor solubility in 
commonly used selected solvents. For example, Table 2.1 illustrates the solubility 
of amoxicillin tri-hydrate in different solvents. 19 During the experimentation, it 
was observed that the addition of the co-former solution to the insoluble 
amoxicillin tri-hydrate solution lead to the solubility enhancement of amoxicillin 
tri-hydrate. Production of successful single crystals was very difficult due to either 
solubility or stability problems. W.r.t stability, in general, β-lactam compounds are 
relatively unstable in aqueous solutions.20 (Amoxicillin degradation discussed in 
chapter 1 page 28). Furthermore, stability data showed that amoxicillin is not 
stable in water, ethanol, methanol, acid and alkali solutions.21 The instability in 
solution form causes a quick degradation of the product and sometimes the 
degradation occurs while the two components are still recanting in the liquid 
phase. The degradation was indicated by a distinct colour change (e.g. white 
powder to green and black).    
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Table 2.1: Solubility of amoxicillin tri-hydrate in selected solvents: 
Solvent Solubility (mg/ml) 
Water 1-10 slightly soluble 
Ethanol 1-10 
Chloroform <0.1 
diethyl ether <0.1 
 
Each co-former has a different solubility profile and the challenge was to ensure that 
both amoxicillin tri-hydrate and the co-former were soluble and stable especially in 
solution phase where degradation occurred spontaneously. Research indicated that 
to control the degradation effect of amoxicillin tri-hydrate a higher stability at an 
acidic pH was preferred.22 
Solvents, pH and temperature 
The choice of the solvent and the appropriate pH was critical to create the amoxicillin 
tri-hydrate co-crystal. Amoxicillin tri-hydrate has a very good solubility in dilute acid 
and dilute solutions of alkali hydroxide. Using a 0.1 N NaOH solution and 0.1 N HCl 
solution gave the best solubility. Also, the solubility in a phosphate buffer (pH 5.8), 
acetone and water were higher compared to other ordinary solvents. W.r.t the 
temperature, the solubility enhanced greatly when the temperature had been elevated. 
 Method of co-crystallization 
Solid based method (grinding and solvent assisted grinding) was the best method for 
amoxicillin tri-hydrate co-crystal formation because of the high stability of the 
components in the solid state and the ability of co-formers to arrange a supramolecular 
structure. It was very difficult to obtain a co-crystal using a liquid based method 
because of solubility and stability concerns, even though when the solubility and 
stability of the solution was great, no crystals were grown. Screening of amoxicillin 
tri-hydrate co-crystals was employed using different co-crystallization methods such 
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as grinding, solvent evaporation, vapour diffusion and recrystallization from the melt. 
The grinding and solvent-assisted grinding methods proved to be a very successful for 
this study. 
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Chapter 3: Presents a brief introduction to the experimental part of the study, the 
successful experimental work (amoxicillin tri-hydrate co-crystal production) and 
the interpretation of all analytical techniques that were applied.  
3.1 Introduction 
The research focused on the production of amoxicillin tri-hydrate co-crystals. However, 
during the literature retrieval stage polymorph screening of each individual compound 
and possible co-crystal formation was investigated given the nature of a thorough pre-
formulation exercise. The fourteen co-formers used in the study were saccharin, oxalic 
acid dihydrate, D-tartaric acid, L-tartaric acid, L-aspartic acid, cinnamic acid, maleic 
acid, salicylic acid, succinic acid, citric acid monohydrate, stearic acid, benzoic 
anhydride, nicotinamide and clavulanic acid (Table 3.1). Table 3.2 illustrates the 
physical properties of amoxicillin tri-hydrate and the selected co-formers. The selection 
of these co-formers was made due to the presence of the carboxylic acid or amino 
functional groups. These functional groups readily produce co-crystals (Chapter 1 page 
18). 
 One of the study challenges was to produce amoxicillin tri-hydrate-clavulanic acid 
single co-crystals. Clavulanic acid, a beta-lactamase inhibitor is available in combination 
with amoxicillin for its synergistic effect and to overcome the degradation of 
amoxicillin by bacterial enzymes. Two studies were conducted in an attempt to 
investigate and understand the interaction of amoxicillin tri-hydrate with potassium 
clavulanate (salt) as a co-crystal.1, 2 By definition (Chapter 1 page 17, Table 1.2), a co-
crystal cannot be prepared from a “salt”. The authors also assumed that the co-crystal 
system was formed via strong hydrogen bonding between the hydrates of amoxicillin 
and potassium clavulanate. Furthermore, the powder X-ray analysis conducted was not 
clear to confirm an interaction.1,2 Both papers failed to  extract and elucidate the 
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structure of the so-called "co-crystal." In this study many experimental methods, 
different ratios, several more co-formers and various solvents were employed to obtain 
co-crystals with amoxicillin tri-hydrate. They were analysed with different thermal and 
spectroscopic techniques. The most successful preparation technique was the product 
obtained by the grinding technique with the different co-formers. This study, however 
was not successful in producing the amoxicillin tri-hydrate/clavulanic acid co-crystal 
during this phase, due to unavailability of clavulanic acid and unsuccessful conversion of 
potassium salt to the free acid, but will continue to be an objective for future work. 
The solubility and stability of amoxicillin was the greatest challenge during the 
experimental work as per discussion in chapter 2. Amoxicillin tri-hydrate has a poor 
solubility in ordinary solvents (slightly soluble in polar and insoluble in non-polar 
solvents) such as chloroform, ethanol and ether and it degrades very fast once a 
solution has been formed.  
All the stable amoxicillin tri-hydrate co-crystals formed and their analytical profiles 
will be explained in this chapter. All the experiments and analysis were repeated in 
triplicate for the purpose of reproducibility, confirmation of results and correlation of 
various analytical techniques applied. 
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Table 3.1: Chemical  structures of (a) amoxicillin tri-hydrate, (b) saccharin, (c) oxalic 
acid di-hydrate, (d) (L,D) tartaric acid, (e) salicylic acid, (f) citric acid monohydrate, 
(g) maleic acid, (h) succinic acid, (i) cinnamic acid (j) stearic acid, (k) L-aspartic acid, 
(l) clavulanic acid, (m) nicotinamide (n) benzoic anhydride. 
(a)
OH
O
NH
O
S
O
OH
NH2
N
H
 
.3H2O 
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O O
NH
O
 
(c) 
 
OH
O
OH
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 Table 3.2: Physical properties of amoxicillin tri-hydrate and selected co-formers. 
 
Compounds 
 
Molecular 
formula 
 
 
M.P (°C)  
 
Solubility in water 
at 25°C 
       
     Uses 
Amoxicillin 
tri-hydrate 
C16H19N3O5S
,3H2O 
194 1-10 mg/ml  Antibacterial 
Saccharin 
 
C7H5NO3S 228.8-229.7 3.44 mg/ml Artificial sweetening 
agent  
Oxalic acid 
dehydrate 
C2H2O4 101-102 143 mg/ml Cleaning and  
bleaching agent 
Tartaric acid C4H6O6 171-174 
(L,D 
tartaric) 
1390 mg/ml Constituent of 
effervescent powders, 
granules and of cool 
drinks  
Citric acid 
monohydrate 
C6H8O7,H2O 135-152 1630 mg/ml  Acidifier and 
flavouring agent 
Nicotinamide 
 
C6H6N2O 128-131 1000 mg/ml Component of vitamin 
B  
Salicylic acid 
 
C7H6O3 158-161  0.002 mg/ml Keratolytic  
Succinic acid C4H6O4 184 76.9 mg/ml Flavouring agent 
Benzoic 
anhydride 
 
C14H10O3 40 0.13 mg/ml Food preservative 
L-aspartic acid C4H7NO4 270 4 mg/ml Amino acid 
Cinnamic acid C9H8O2 132-134 0.4 mg/mL  Antimicrobial 
preservative; 
pharmaceutical aid  
Maleic acid 
 
C4H4O4 135 780 mg/ml  To form maleate salts 
of the drugs 
Stearic acid 
 
C18H36O2 69.6 0.003 mg/ml As lubricant in 
making compressed 
tablet  
Clavulanic  
Acid 
C8H9NO5 117.5-118 300 mg/ml 
(potassium salt) 
Beta-lactamase 
inhibitor 
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3.2 Identification of the compounds: 
Fourier transform infrared (FTIR) analysis is a very useful technique for compound 
identification. It was used to identify amoxicillin tri-hydrate and the co-formers. All 
compounds were tested in the powder form. The frequencies of each significant band 
confirmed their identification within the spectra when compared to the British 
Pharmacopoeia 2008 (BP)3 standards and/or that were listed in the Sci-finder database 
2012.4 Each IR spectrum is found in Appendix A and the characterized bands for each 
compound detailed and listed in Table 3.3 below. 
Amoxicillin tri-hydrate. 
 
Amoxicillin was used as the hydrated form (tri-hydrate). The water of crystallization 
(OH stretching) peak appears at 3520cm-1 (Figure 3.1).5 The beta-lactam (C=O) 
stretching is located at 1776 cm-1, the aromatic ring frequency at 1519 cm-1 and the 
amide C=O frequency at 1688 cm-1.6 The spectra met the BP 2008 standards.3  
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Figure 3.1: FTIR spectrum of amoxicillin tri-hydrate. 
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Table 3.3: FTIR characteristic frequency bands of amoxicillin tri-hydrate and co-
formers. 
Compounds Experimental 
frequency  
Standard 
frequency 
Functional groups 
Amoxicillin  
tri-hydrate 
3452 
1772 
1684 
1519 
1312 
 
1328 
3520 
17756 
16866 
15176 
1314 
 
1327 
OH stretching 
Beta-lactam C=O  
Amide C=O stretching 
Aromatic ring 
Fused thiazolidine beta-lactam skeletal 
mode. 
COO- symmetric stretch. 
Saccharin 972 
1715 
3400,3093 
1592 
9757, 8 
17227, 9 
3410,31007 
15957 
S-N-C 
O=C-NH 
CO-NH 
Aromatic-C=C- 
Oxalic acid  
di-hydrate 
1613 
3415 
1725-170010, 11 
Around 300010 
C=O 
O-H 
(L,D)-tartaric acid 1715 
3096 
1725-170010, 11 
Around 300010 
C=O 
O-H 
Citric acid 
monohydrate  
1721  
2544,2957 
1725-170010 
around 300010 
C=O 
O-H 
Nicotinamide 3357 3500-330010 N-H 
Salicylic acid 3231 
1609 
2500-300011 
1615-158011 
O-H 
Aromatic ring C=C- 
Succinic acid 2929 2500-3000 11 O-H carboxylic 
Benzoic anhydride 1827 
1773 
1800-183010 
1740-177510 
C=O 
C=O 
L-aspartic acid 2951 
1684 
3400-3200 12, 13 
169114 
NH2 
C=O 
Cinnamic acid 2828 
1577 
1495 
2500-3000 11 
1615-1580 11 
1510-1450 11 
O-H 
C=C 
Aromatic 
Maleic acid 1703 1725-170010 C=O 
Stearic acid 1698 
938 
171015 
940 15 
C=O Stretching 
Bending OH-H 
Clavulanic acid Not recorded 
due to 
unobtainability 
1020-1360 
1000-1280 
1710-1780 
2500-3000 
Tertiary amine 
Ether group 
C=O 
OH 
 
Comment:  other techniques were used for compound identification, such as differential 
scanning calorimetry (DSC) to determine the melting point and powder X-ray diffraction 
(PXRD) to determine the fingerprint diffraction pattern of the parent compounds. The 
FTIR spectra, DSC diagram and PXRD pattern of all compounds are presented in 
Appendix A. 
 
 
 
 
 64 
 
3.3 Co-crystals of amoxicillin tri-hydrate. 
 Amoxicillin tri-hydrate 
Amoxicillin tri-hydrate (C16H19N3O5S.3H2O) is widely used as a broad spectrum 
antibiotic. It belongs to the beta-lactam antibiotics.16 Chemically, amoxicillin is an α-
amino-p-hydroxybenzyl penicillin.17 Its structure (Table 3.1) is characterized with a 
thiazolidin ring attached to a beta-lactam ring that carries a secondary amino group 
(RNH-).18 The presence of a hydroxyl, amino and carboxylic group within the structure 
provides an opportunity for amoxicillin tri-hydrate to act as a hydrogen donor molecule 
and to bind non-covalently with other compounds (co-formers) to form a co-crystal. 
Amoxicillin crystals are orthorhombic, in space group P212121 with four molecules in 
the unit cell. The thiazolidine ring confirmation has a sulphur atom out of the plane 
formed by the other four atoms.5 
Several experiments were conducted to produce amoxicillin tri-hydrate co-crystals. 
Table 3.4 is representative of the experiments conducted to produce possible co-
crystals. Appendix B may be consulted for a full overview of all experiments conducted 
in this study.  
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Table 3.4: Typical experiments conducted to produce co-crystals of amoxicillin tri-
hydrate. 
API Co-former Ratio Method Solvent Result 
Amoxicillin 
tri-hydrate 
Saccharin 1:1 Solvent 
evaporation 
Water Negative 
Amoxicillin 
tri-hydrate 
L-aspartic 
acid 
1:1 Dry grinding  - Negative 
Amoxicillin 
tri-hydrate 
Succinic acid 1:1 Dry grinding - Positive 
Amoxicillin 
tri-hydrate 
Maleic acid 1:1 Vapour diffusion Acetone 
chloroform 
Negative 
Amoxicillin 
tri-hydrate 
Nicotinamide 1:1 Solvent assisted 
grinding 
HCl solution Negative 
Amoxicillin 
tri-hydrate 
Saccharin 1:1 Heating - Positive 
Amoxicillin 
tri-hydrate 
Salicylic acid 1:0.7 Solvent 
evaporation 
NaOH 
solution 
Negative 
Amoxicillin 
tri-hydrate 
Cinnamic 
acid 
2:1 Solvent assisted 
grinding 
Water Negative 
 
The following are the successful amoxicillin tri-hydrate co-crystals with their analytical 
profiles. 
3.3.1 Amoxicillin tri-hydrate-saccharin co-crystal. 
 Saccharin 
Saccharin (C7H5NO3S) is a synthetic sweeting agent present in many pharmaceutical 
preparations.19 It is used as an excipient in low concentrations.19 Saccharin is a weak 
acid20 and its structure contains both hydrogen donors (N-H) and acceptors (S=O) in 
the molecular structure (Table 3.1).21 This  facilitates good co-former characteristics for 
co-crystal formation.21 
1. AMS1 
Preparation 
Amoxicillin tri-hydrate was neatly ground with saccharin in a 1:1 ratio. 20 mg of 
amoxicillin tri-hydrate was manually grounded with 0.0087 mg of saccharin using a 
mortar and pestle for 5 minutes to obtain a homogenous mixture. The grounded sample 
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was transferred to a porcelain crucible wrapped with aluminium foil and heated at a 
temperature of 80 °C for 30 minutes on a hot plate. The aluminium foil retained the 
heat evenly throughout the duration of 30 minutes. AMS1 was formed after the heat 
had been applied. 
Analytical analysis of AMS1 
A. Thermal analysis 
Differential scanning calorimetry (DSC) 
The DSC figure 3.2 shows a broad melt of the sample peaking at 176 °C which is a 
different melt compared to the two parent compounds. Amoxicillin tri-hydrate melt is 
very broad between 186 °C -194 °C and saccharin has a sharp melting point at 228 °C.  
 
 
 
 
Figure 3.2: DSC thermogram of AMS1. 
 
The DSC also indicates a loss of water molecules from AMS1 in the range between 87-
138 °C followed by the exothermic reaction between 152-195 °C. The DSC curve of the 
co-crystal therefore suggests that both amoxicillin tri-hydrate and saccharin melting 
peaks disappeared during the preparatory grinding process. 
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Hot stage microscopy (HSM) 
A small quantity of the sample was taken and analysed under the HSM (Figure 3.3). 
One drop of silicon oil was added to the sample. The role of the oil was to ascertain 
whether water was present in AMS1 which is usually indicated by bubble formation 
prior to melting. At 100 °C bubbles were released indicating the loss of water. The 
onset of the melt of the sample was observed at 150 °C and decomposition started at 
190 °C. The decomposition was indicated by spontaneous bubbling of the co-crystal. 
This result correlates with the DSC result. 
 
(a)  100 °C           (b) 150 °C 
              
      
 (c) 190 °C 
          
Figure 3.3: HSM pictures of (a) water release, (b) melting of AMS1 and  
(c) decomposition of AMS1. 
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 Thermogravimetric analysis (TGA) 
TGA analysis of AMS1 (Figure 3.4) was characterized with a noisy line, this might be 
due to the heat transfer into the sample during sample heating which lead to sample 
expansion at first, then fragmentation and bubbles being released upon water loss. 
The calculated mass loss was 1.78% (n=0.52) prior to the melt of the compound. The 
trihydrate is thus lost from the original structure and less water is found to be present 
in the co-crystal AMS1, i.e. n=0.52, half a water molecule. 
  
Figure 3.4: TGA analysis of AMS1. 
 
 
B. Spectroscopic analysis  
Infrared spectroscopy (FTIR) 
The FTIR spectrum of AMS1 (Figure 3.5) contains all the amoxicillin tri-hydrate peaks 
which mean that the new compound still holds the main functional groups that 
characterize amoxicillin tri-hydrate. Furthermore, a few peaks of saccharin is also 
identified in the spectrum especially those contributing to the hydrogen bond 
interaction with amoxicillin tri-hydrate. 
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Figure 3.5: FTIR spectra of (a) AMS1, (b) amoxicillin tri-hydrate and  
(c) saccharin 
 
Figure 3.6: Possible interaction sites from FTIR spectra for amoxicillin tri-
hydrate and saccharin to form AMS1. 
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Table 3.5: Peaks shifts of AMS1 FTIR spectrum. 
AMS1 Amoxicillin tri-hydrate frequency 
band and functional group 
Saccharin peak frequency 
band and functional group 
1719.42 - 1715.29 (C=O) 
Intensity 
decrease. 
3158.73 (O-H) - 
A slight shift at the C=O group of saccharin is accompanied with a decrease of the O-H 
stretching peak intensity within the amoxicillin tri-hydrate structure. This shift and 
decrease in peak intensity emphasises a hydrogen bond formation between the two 
components (Table 3.5 and Figure 3.5).    
H1-nuclear magnetic resonance (H1-NMR). 
From liquid NMR, the homogenousity of AMS1 is ensured which indicates the 
presence of the two parent compounds. H1-NMR spectra of AMS1 is attached in 
Appendix C. The two components were estimated to be present in a 1:1 ratio. 
 The method employed to establish the ratio was as follows: the two ingredients (co-
formers) were expected to be part of an equilibrium in order for them to form the co-
crystal. The two different chemicals each exhibit NMR resonant signals for the 
corresponding chemical environments slightly differently to each other. Choosing two 
peaks, one from that corresponding to a proton in one compound and one from the 
other, then identifying which protons in each of the molecules corresponds to these 
peaks, and calculating the expected integrals. If the observed peak's integrals are in the 
ratio of 1:1, then the co-crystal is a 50:50 mixture of product to reactant.  
C. Powder X-ray diffraction (PXRD). 
The PXRD pattern of AMS1 (Figure 3.7) differs compared to the individual compounds 
indicated by the appearance of new peaks and the disappearance of parent compound 
peaks at 4.5, 5, 7, 13, 16, 18.5 and 16 2 θ°. This confirms the interaction between 
amoxicillin tri-hydrate and saccharin. 
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Figure 3.7: PXRD patterns of AMS1, amoxicillin tri-hydrate and saccharin. 
 
D. Scanning electron microscope (SEM). 
Figure 3.8 illustrates the morphology of AMS1 compared to the morphology of 
amoxicillin tri-hydrate under different magnification power. Both are rectangular in 
shape, however AMS1 has a wider and longer crystal shape with a particle size of 8.2 
μm compared to amoxicillin tri-hydrate which has a particle size of 2.9 μm. 
                                
(a)                                                                    (b) 
               Figure 3.8: SEM pictures of (a) amoxicillin tri-hydrate and (b) AMS1. 
 
To conclude, the same result was obtained when the experiment was carried out at a 
       lower temperature (30 °C) using 1:1 and 1:0.5 ratios of the co-forming materials. 
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      2.  AMS2 
       Preparation: 
Amoxicillin tri-hydrate was neatly ground with saccharin in a 1:0.7 ratio using a 
mortar and pestle. The grinding was conducted at room temperature for 30 minutes. 
The grounded material was called AMS2 and analysed as follows: 
      Analytical analysis of AMS2: 
A. Thermal analysis 
  DSC 
Two peaks appeared on the DSC thermogram of AMS2 (Figure 3.9). The first peak 
represents the water loss of amoxicillin tri-hydrate. It ranges between 90-135 °C. The 
second peak indicates the melt of the sample AMS2. The onset of melt occurred at 147 
°C which was earlier than the melt of the two parent compounds. Decomposition 
appeared in the range of 165-170°C. 
 
Figure 3.9: DSC thermogram of AMS2. 
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  HSM 
The observed result of HSM (Figure 3.10) is clear and correlates with the DSC result. 
The bubbling indicating water loss commenced at 101°C followed by the onset of the 
melt commencing at 147 °C and decomposition commenced at 170°C. Decomposition 
was identified by the spontaneous bubbling of AMS2. 
 
               (a)  30 °C                                                  (b) 130 °C 
                                 
 
                 (c) 150 °C                                                (d) 171 °C   
   
Figure 3.10: HSM of AMS2. (a) AMS2 at room temperature, (b) Water 
loss of AMS2, (c) Melt of AMS2 and (d) Decomposition of AMS2 
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 TGA  
Figure 3.11 shows the TGA analysis of AMS2 which confirms the water loss of the 
previous 2 thermal analysis. 1.63% (n=0.53) was the calculated amount of water loss. 
                                          Figure 3.11: TGA analysis of AMS2. 
B. Spectroscopic analysis : 
FTIR. 
The FTIR spectrum of AMS2 (Figure 3.12) is similar to the amoxicillin tri-hydrate 
spectrum and includes a few significant saccharin peaks. The most pronounced shifts 
for saccharin are those involving the C4O group and the O25H and N19H for the 
amoxicillin tri-hydrate structure (Table 3.6 and Figure 3.13). 
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Figure 3.12: FTIR spectrum of (a) AMS2, (b) amoxicillin tri-hydrate and 
(c) saccharin. 
 
 
Figure 3.13: Possible interaction sites from FTIR spectra for amoxicillin tri-
hydrate and saccharin to form AMS2. 
 
 
 
 
 
 
 
 76 
 
Table 3.6: Peak shifts of AMS2 FTIR spectrum 
AMS2 Amoxicillin tri-hydrate frequency band  
and functional group 
Saccharin frequency band 
and functional group 
1720.22 - 1715.29 (C=O) 
1462.86 1450.62 (CC benzene) +(CH benzene) + 
(O25H)+(C16H)  
1458.17 (C-C stretching of 
benzene ring ) 
901.06 
 
922.37(C15C16H,C2C5)+(NH)+ (C7C3,C3C8) - 
 
H1-NMR analysis 
The NMR spectrum confirms sample homogenousity. The estimated ratio of the co-
crystal formers is a 1:1 ratio.  The spectrum is attached to Appendix C.  
 
 C. PXRD 
The PXRD pattern recorded for AMS2 differs from the parent components. The 
pattern also differs from AMS1 at 2θ 6°and19° indicated by the arrows. The pattern is 
represented in Figure 3.14.  
 
Figure: 3.13 PXRD pattern of AMS1, AMS2, amoxicillin tri-hydrate and 
saccharin. 
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D. SEM 
Figure 3.15 shows the different surface morphology of amoxicillin tri-hydrate and 
AMS2 under the same magnification powers. AMS 2 is characterized as a longer, wider 
shaped particle with size dimension of 9.3 μm where amoxicillin tri-hydrate has a 
particle size of 2.9 μm. 
                 
(a)      (b) 
Figure 3.15: SEM pictures of (a) AMS2, (b) amoxicillin tri-hydrate. 
 
Conclusion: 
Two different co-crystals of amoxicillin tri-hydrate formed with saccharin. The co-
crystals produced were characterized with thermal, spectroscopic and X-ray diffraction 
analytical methods. The two co-crystals (AMS1 and AMS2) have different melting 
point peaks (176 °C and 155 °C respectively) as indicated by DSC and HSM. The same 
percentage water loss was, however evaluated, i.e. 1.78% (n= 0.52) and 1.63% (n= 0.53). 
Even though the percentage water loss was the same for both AMS1 and AMS2, the 
PXRD pattern and FTIR spectrum for each were different. This may possibly indicate 
that AMS1 and AMS2 may well be polymorphs of each other.  
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3.3.2  Amoxicillin tri-hydrate- oxalic acid co-crystal. 
 Oxalic acid. 
Oxalic acid (ethanedioic acid) is a dicarboxylic acid22 and considered as one of the simple 
diprotic organic acids.23 It is present in two crystalline forms, the stable phase 
(orthorhombic alpha phase) and metastable phase (monoclinic beta phase).24 The 
hydrated form is used in this study. Oxalic acid is one of the carboxylic acids known to 
form co-crystals.25-27 Carboxylic acids contain a hydroxyl group (O-H) and a carbonyl 
group (COOH) within its structure28 which offers the carboxylic acid function as a 
hydrogen bond donor and acceptor. Many drugs formed a co-crystal with oxalic acid 
such as Gabapentin25 theophylline 26 and caffeine.27a 
 
AMO 
Preparation: 
 The experiment was prepared by the solvent assisted grinding method. Amoxicillin tri-
hydrate was combined with oxalic acid di-hydrate in a 1:1 ratio. In a mortar, the two 
compounds were grounded manually and acetone was added drop-wise to the mixture 
while grinding. The time of grinding lasted for 30 minutes.  
Analytical analysis of AMO: 
A. Thermal analysis 
DSC 
Figure 3.16 shows a very small broad endothermic peak between 46-52 °C which 
indicates the presence of the solvent, acetone (boiling point of acetone is 56 °C). The loss 
of water occurred in the range between 68-87 °C. The melt of the co-crystal AMO 
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appeared small and broad between 145.6-158 °C which differs compared to the melt of 
the primary ingredients.  
 
Figure 3.16: DSC thermogram of AMO. 
 
HSM 
At 75 °C, bubbling occurred indicating the release of water molecules as shown in 
figure 3.17. The melt was observed within the same range as the DSC melting peak 
between 140-150 °C. At 170 °C the sample started to decompose. The decomposition 
was specified by a black discolouration of the sample with spontaneous bubbling. 
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(a) 75 °C     (b)155 °C 
                    
 
(c)170 °C 
    
Figure 3.17: HSM of AMO illustrating (a) water loss, (b) melt of AMO and the 
(c) decomposition stage of AMO. 
 
TGA 
A small amount of water loss was shown by the AMO TGA analysis (Figure 3.18). This 
confirmed the water loss peak identified on the DSC thermogram. The calculated loss 
was 1.5% (n=0.4). 
 
Figure 3.18: TGA analysis of AMO. 
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B. Spectroscopic analysis  
FTIR spectroscopy 
All significant IR peaks of amoxicillin tri-hydrate are saved in the AMO spectrum 
(Figure 3.19) with changes in the intensity and frequency of the peaks. Shift of the 
hydroxyl peak of the oxalic acid at 3415.25 cm-1 to a lower frequency (3384.92 cm-1) 
together  with loss of the peak at 3523.80 cm-1  indicates to the OH stretching (water 
of crystallization) for amoxicillin tri-hydrate. Furthermore, the peak at 1772.26 cm-1 
(C=O) within the amoxicillin tri-hydrate structure shifts significantly to 1779.08 cm-1,  
possibly indicating a hydrogen bond formation. Table 3.7 and Figure 3.20 illustrate 
the FTIR peak shifts of AMO. 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
a
b
c
2931.38
2162.96
1779.08
1690.26
1619.28
1516.71
1461.07
1413.85
1374.91
1320.94
1257.56
1223.65
1182.67
1124.45
1081.61
1046.06
833.39
805.24
743.92
2969.92
1772.26
1684.81
1615.28
1576.40
1519.29
1481.52
1450.62
1396.00
1378.30
1361.21
1328.00
1312.64
1282.43
1247.78
1217.80
1196.22
1177.72
1144.28
1119.93
1076.63
1021.01
1002.67
986.18
922.37
872.94
847.67
837.79
732.85
695.33
3415.25
1437.16 1113.69
719.20
Figure 3.19: FTIR spectrum of (a) AMO, (b) amoxicillin tri-hydrate and 
 (c) oxalic acid di-hydrate 
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 .  
Figure 3.20: Possible interaction sites of amoxicillin tri-hydrate and oxalic acid 
di-hydrate to form AMO. 
 
   Table 3.7 Peak shifts of AMO spectrum. 
AMO  Amoxicillin tri-hydrate band 
frequency and functional group 
Oxalic acid di-hydrate band 
frequency and functional 
group 
1461.07  1481.52 (N10C15,N10H,C5H) - 
1413.85  1450.62 (CC,CH benzene ring 
,O25H,C16H )  
1437.16 (C=O) 
1374.91 1396 (CH3) - 
1320.94  1328 (CC,CH benzene 
ring,O25H) 
- 
1257.56  1247 (CH) - 
 
 
  H1-NMR analysis  
Since this preparation includes oxalic acid, which cannot be detected by 1D 1H 
NMR,27b due to the nature of oxalic acid di-hydrate, where the presence of two 
carboxylic groups cannot be predicted.  The resultant NMR spectrum only identified 
the presence of the amoxicillin tri-hydrate (see Appendix C for spectrum). The two 
compounds are, however present in 1:1 ratio based on the DSC result. Ratio 
estimation was estimated based on the DSC result since both the parent compounds 
were not present during the melting stage and a pure co-crystal had formed.   
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C. PXRD 
The PXRD pattern of AMO is presented in Figure 3.21.The pattern showed differences 
at 5, 8.8, 11, 14.2, 15.5, 19, 36.5 and 39.6 2θ° values compared to the individual 
compounds. This is an indication of the formation of a new form. 
 
 
 
Figure 3.21: PXRD pattern of AMO (a) Amoxicillin tri-hydrate (b) and (c) Oxalic 
acid di-hydrate. 
 
D. SEM 
Under the scanning electron microscope, the AMO crystal (Figure 3.22) was 
characterized as small, spherical shaped particles with a small variation in the particle 
size between each particle. Upon comparison, the amoxicillin tri-hydrate particle size of 
2.9 μm  was significantly larger than the AMO particle size of 0.21 μm. 
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  (a)       (b)  
Figure 3.22: SEM pictures of (a) AMO and (b) amoxicillin tri-hydrate. 
 
Note: 
The same co-crystal was produced by neat grinding of amoxicillin tri-hydrate with 
oxalic acid di-hydrate in the same ratio. Hence, the solvent makes no significant impact 
on the co-crystal reaction between the co-formers. 
 
3.3.3 Amoxicillin tri-hydrate -D-tartaric acid co-crystal. 
 D-tartaric acid 
Tartaric acid (2,3-dihydroxybutanedioic acid) is a diprotic acid existing as three 
stereoisomers, the meso-compound and enantiomers.29 
AMDT 
Preparation: 
A stoichiometric amount of amoxicillin tri-hydrate was ground with a stoichiometric 
amount of D-tartaric in a 1:1 ratio. During the grinding process a few drops of prepared 
phosphate buffer (pH 5.8) was added. The grinding continued manually in a mortar 
with a pestle at room temperature for 30 minutes.  
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Analytical analysis of AMDT: 
A. Thermal analysis 
DSC 
The DSC thermogram showed a broad endotherm between 111-135 °C, preceded by a 
slight bump (80-100 °C), indicating loss of solvent. The peak at 128 °C represents the 
melt of the sample which differs from the melt of amoxicillin tri-hydrate and D-tartaric 
acid (Figure 3.23). After 160 °C decomposition of AMDT is illustrated. 
 
 
Figure 3.23: DSC thermogram of AMDT. 
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HSM 
Under HSM, at 100 °C the sample particles started to fragment and bubbling occurred 
which indicated a loss of solvent. Between 120-130 °C the sample melted clearly. The 
entire sample started to degrade and faded from 160 °C onwards (Figure 3.24). 
(a)30 °C    (b)100°C 
        
(c)125 °C    (d) 160 °C 
         
Figure 3.24: HSM pictures of (a) AMDT at room temperature, (b) 
fragmentation and solvent loss, (c) AMDT melt and (d) decomposition of 
AMDT. 
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TGA 
The TGA analysis of AMDT (Figure 3.25) indicates a mass loss between the 
temperatures of 30-170 °C. 11.11% (n=3.5) was calculated as the theoretical mass loss. 
 
Figure 3.25: TGA analysis of AMDT. 
 
B. Spectroscopic analysis 
 
FTIR spectroscopy 
The AMDT IR spectrum (Figure 3.26) is characterized with short intense peaks 
compared to amoxicillin tri-hydrate. A significant shift of both carbonyl and hydroxyl 
group of D-tartaric acid is detected and highlighted in Table 3.8. A shift in the carbonyl 
and hydroxyl group of the carboxylic acid is possibly due to a hydrogen bond.10 
Furthermore the shift occurred at the C8O14 and O13H of amoxicillin tri-hydrate as well 
which further indicates that there is a definite interaction between the two components.  
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
a
b
c
3039.66
1774.39
1685.78
1614.72
1578.17
1518.95
1484.35
1396.36
1378.31
1328.44
1312.88
1282.19
1247.95
1120.29
1077.11
1021.86
985.97
838.00
733.00
2969.92
1772.26
1684.81
1615.28
1576.40
1519.29
1481.52
1450.62
1396.00
1378.30
1361.21
1328.00
1312.64
1282.43
1247.78
1217.80
1196.22
1177.72
1144.28
1119.93
1076.63
1021.01
1002.67
986.18
922.37
872.94
847.67
837.79
732.85
695.33
3398.43
3326.43
3092.52 2606.10
1732.53
1445.46
1396.09
1318.01
1252.49
1217.95
1185.35
1127.75
1027.90
991.83
939.55
871.59
828.60
786.89
733.54
661.98
 
Figure 3.26: FTIR spectra of (a) AMDT, (b) amoxicillin tri-hydrate and (c) D-
tartaric acid. 
 
 
Figure 3.27: Possible interaction sites between amoxicillin tri-hydrate and D-
tartaric acid to form AMDT. 
 
Table 3.8 Peak shifts of AMDT spectrum.  
AMDT Amoxicillin tri-hydrate band 
frequency and functional group 
D-tartaric acid band 
frequency and functional 
group 
2964.2 2969.92 (C3H) 3092.5 (O-H) 
1774.3 1772.62(C8O14+C3H+O13H,OH) 1732.5 (C=O) 
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H1-NMR analysis 
The AMDT spectrum indicates a homogenous preparation, however tartaric acid 
contains two asymmetric centres which makes it difficult to determine the ratio of the 
D-tartaric acid present in the sample. DSC was once again used as a predictor for the 
ratios. Since both parent compounds were not present on the DSC thermogram, the 
ratio is predicted to be 1:1.  
 
C. PXRD 
The PXRD pattern of AMDT (Figure 3.28) shows distinct differences at the 2θ angles 
12.5°,18°, 30°, 40° and together with the disappearance of some co-former peaks within 
the AMDT pattern confirmed the new co-crystal form. 
 
 
Figure 3.28: PXRD pattern of AMDT, amoxicillin tri-hydrate and D-tartaric 
acid. 
 
D. SEM 
The electron microscope images, (Figure 3.29) of AMDT characterized spherical 
shaped particles compared to amoxicillin tri-hydrates characteristic long, rectangular 
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crystal. The AMDT particles have a large particle size of 13.2 μm whereas,  amoxicillin 
tri-hydrate particle size is 2.9 μm.   
      
(a)       (b) 
      Figure 3.28: SEM pictures of (a) amoxicillin tri-hydrate and (b) AMDT. 
 
3.3.4 Amoxicillin tri-hydrate – nicotinamide co-crystal. 
 Nicotinamide 
Nicotinamide is pyridine-3-carboxamide (Table 3.1). It is a water soluble vitamin30 used 
as a component of vitamin B.3 Nicotinamide has anti-inflammatory properties used for 
skin inflammation conditions.31 Nicotinamide has the ability to function as a hydrogen 
bond donor which provides it with a high chance to interact non-covalently with 
amoxicillin tri-hydrate. Many co-crystals have been formed using nicotinamide such as 
carbamazepine-nicotinamide co-crystal. 32  
AMN 
Preparation: 
The co-crystal was prepared by manual grinding of amoxicillin tri-hydrate with 
nicotinamide in a stoichiometric ratio of 1:1 for 30 minutes. Two drops of phosphate 
buffer (pH 5.8) was added during the grinding procedure as a solvent and to facilitate 
the reaction process. 
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Analytical analysis of AMN: 
A. Thermal analysis 
DSC 
AMN DSC thermogram (Figure 3.29) was characterized with a sharp peak in the range 
of 95-98 °C which represents the loss of water from the co-crystal. A broad melting 
peak between 144 -165 °C indicated the AMN melt. 
 
 
   Figure 3.29: DSC thermogram of AMN. 
 
 
HSM 
For thermal behaviour investigation of AMN (Figure 3.30), a small amount of the 
sample was placed under the HSM and investigated using silicon oil for the purpose of 
solvent resolution. A few bubbles were released at 90 °C indicating the presence of 
solvent. The sample started to melt slowly at 145 °C until decomposition commenced at 
170 °C. The decomposition was presented by a brown discoloration of the sample.  
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        (a) 25 °C     (b) 90 °C  
        
 
                  (c)145°C (d)170°C
 
         
 
Figure 3.30: HSM of AMN illustrating (a) AMN at room temperature, (b) 
release of solvent, (c) AMN melt and (d) decomposition of AMN. 
 
TGA 
Figure 3.31 represents the TGA analysis of the sample. The TGA curve confirms 
the DSC thermogram. The calculated mass loss equalled to 10.3%, which amounted 
to 3.1water molecules. 
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Figure 3.31: TGA analysis of AMN 
Spectroscopic analysis 
FTIR spectroscopy 
From the IR spectra of AMN (Figure 3.32), slight shifts of amoxicillin tri-hydrate peaks 
were noticeable, for example the peak at 3523 cm.-1 The more significant shift was for 
the nicotinamide peak that appeared at 3357.3 cm-1. The nicotinamide band represents 
the primary amide group N-H and the amoxicillin tri-hydrate peak represents the 
stretching vibration of the hydroxyl group for the water of crystallization. Peak shifts 
and their functional groups are presented in Table 3.9 and Figure 3.33. 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
a
b
c
3364.68
3157.42 2970.11
1773.24
1681.92
1615.19
1575.23
1518.95
1483.12
1451.05
1422.82
1395.41
1378.41
1361.23
1328.05
1312.57
1282.35
1248.32
1217.93
1202.35
1177.74
1144.61
1120.21
1076.66
1029.53
986.11
922.45
872.74
847.62
837.77
732.57
701.72
3452.38
3519.84
2969.92
1772.26
1684.81
1615.28
1576.40
1519.29
1481.52
1450.62
1396.00
1378.30
1361.21
1328.00
1312.64
1282.43
1247.78
1217.80
1196.22
1177.72
1144.28
1119.93
1076.63
1021.01
1002.67
986.18
922.37
872.94
847.67
837.79
732.85
695.33
3452.38
3523.80
3357.30
3149.40
2786.35
1673.74
1614.70
1593.00
1574.86
1485.90
1421.73
1339.82
1231.38
1202.07
1153.89
1124.59
1091.59
1028.58
969.41
936.00
828.17
776.84
700.80
3519.84
 
Figure 3.32: FTIR spectra of (a) AMN-1, (b) Amoxicillin tri-hydrate and (c)    
Nicotinamide. 
 
 
Figure 3.33: Possible interaction sites between amoxicillin tri-hydrate and 
nicotinamide to form AMN. 
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Table 3.29: Peak shifts of AMN FTIR spectrum 
AMN Amoxicillin tri-hydrate frequency 
band and functional group 
Nicotinamide frequency 
band and functional group 
3364.6 -      3357.3 (N5-H)                  
3515.8 3523(O-H stretch ,water of 
crystallization) 
-     
 
  
H1-NMR analysis 
The NMR spectrum showed a homogenous preparation, the ratio of amoxicillin tri-
hydrate to nicotinamide is 1.2:1. The spectrum is attached in Appendix C. 
 
B. PXRD 
PXRD data (Figure 3.34) confirmed the formation of amoxicillin tri-hydrate–
nicotinamide co-crystal where the PXRD pattern of AMN differs at 11.3°, 17.4°, 24.6°, 
28.4° and 30.1 2° compared to the parent compounds. 
 
Figure 3.34: PXRD patterns of AMN and the parent components 
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C.  SEM 
Figure 3.35 shows the morphology difference between the pure amoxicillin tri-hydrate 
and AMN. A significant particle size difference was observed. Amoxicillin tri-hydrate 
showed a particle size of 2,95 μm whereas the AMN particle size was 7,15 μm. 
                          
(a)         (b) 
 Figure 3.35: SEM pictures of (a) amoxicillin tri-hydrate and (b) AMN. 
3.3.5 Amoxicillin tri-hydrate - salicylic acid co-crystal. 
 Salicylic acid 
Salicylic acid is O-hydroxybenzoic acid. The structure is illustrated in Table 3.1. It has 
bacteriostatic and fungicidal properties. The presence of the carboxyl and hydroxyl 
groups within the salicylic acid structure provides the opportunity to form a co-crystal 
with amoxicillin tri-hydrate. 
AMSL 
Preparation: 
 Amoxicillin tri-hydrate was mixed with salicylic acid in a 1:1 ratio, the mixture was 
ground manually using a mortar and pestle for 30 minutes with a few drops of acetone.  
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Analytical analysis of AMSL: 
A. Thermal analysis 
 
DSC 
DSC thermogram of AMSL showed a very sharp endothermic peak between 107-115 
°C which has a different melting point compared to the former substances (melting of 
amoxicillin tri-hydrate is very broad between 186-194 °C and the melting point of 
salicylic acid is very sharp between 158-160 °C). The co-crystal showed an early 
decomposition at 130 °C as represented in the thermogram below (Figure 3.36). 
 
Figure 3.36: DSC thermogram of AMSL. 
 
HSM 
Upon heating AMSL (Figure 3.37) under the HSM, the onset of the co-crystal melt was 
observed early from 105 °C. The melt was accompanied with a yellow discoloration. 
This indicated the early degradation of AMSL which was further pronounced by a 
brown discolouration together with spontaneous bubbling which commenced at 135 °C. 
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(a)26 °C     (b)105 °C 
      
  
     (c)135 °C 
      
Figure 3.37: HSM pictures of AMSL, (a) Sample at room temperature, (b) AMSL 
melt and (c) Decomposition of AMSL. 
 
 TGA 
No mass loss was shown by the TGA analysis (Figure 3.38) of AMSL. This proved that 
both the DSC and HSM data were indeed correct.  
 
Figure 3.38 TGA analysis of AMSL. 
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B. Spectroscopic analysis 
FTIR  
The co-crystal spectrum (Figure 3.39) includes the amoxicillin tri-hydrate peaks with 
differences in the intensity and slight shifts. A significant shift occurred within the 
salicylic acid spectra at 1658.77 cm-1 where a carboxylic C=O group frequency was 
located. Loss of the phenol O-H stretch peak at 3158.73 cm-1 within the amoxicillin tri-
hydrate spectra as well as shifts of the water of crystallization peak confirms the 
interaction between the two components (Figure 3.40 and Table 3.10). 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
a
b
c
2970.52
2612.72
1773.77
1683.47
1658.77
1612.75
1578.15
1519.30
1482.76
1464.15
1445.60
1396.12
1378.59
1361.57
1326.49
1295.99
1283.07
1247.73
1210.79
1178.27
1156.76
1144.88
1120.11
1076.76
1031.23
1021.29
986.13
964.84
891.56
873.28
847.81
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785.46
758.85
733.32
695.32
658.90
3531.74
3448.41
2969.92
1772.26
1684.81
1615.28
1576.40
1519.29
1481.52
1450.62
1396.00
1378.30
1361.21
1328.00
1312.64
1282.43
1247.78
1217.80
1196.22
1177.72
1144.28
1119.93
1076.63
1021.01
1002.67
986.18
922.37
872.94
847.67
837.79
732.85
695.33
3523.80 2619.04
3158.73
3231.62
2851.58 2591.24
1654.88
1609.43
1579.23
1481.75
1464.77
1441.21
1382.82
1324.05
1291.01
1243.04
1207.72
1153.56
1089.18
1030.21
964.32
887.27
867.19
852.08
783.87
690.51
657.81
 
Figure 3.39: FTIR spectra of (a) AMSL, (b) Amoxicillin tri-hydrate and (c) 
Salicylic acid. 
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Figure 3.40: Possible interaction sites of amoxicillin tri-hydrate and salicylic 
acid to form AMSL (water molecules excluded). 
 Since both the TGA and DSC results display no water present in the co-crystal, it is 
safe to assume that water molecules are not part of the interactions between the two 
co-formers. 
  Table 3.10: Peak shifts of AMSL FTIR spectrum. 
AMSL  Amoxicillin tri-hydrate 
frequency band and 
functional group. 
Salicylic acid band frequency 
and functional group 
Lost 3158.7 (Phenol O-H) - 
2612.7 2619.0 - 
3531.7 3523.8 (O-H stretch)  
1658.7 - 1654.8  (C=O carboxylic) 
 
H1-NMR analysis 
NMR spectroscopy indicated a homogenous sample and the co-crystal is predicted to 
form in a stoichiometric ratio of 1:1. 
 
C. PXRD 
Differences at 24.8, 28, 30.2° in the AMSL PXRD diffraction pattern (Figure 3.41) 
compared to the parent compounds indicated a new form and confirmed the co-crystal 
formation. 
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Figure 3.41: PXRD patterns of AMSL and the parent components. 
 
 
D. SEM 
The morphology of AMSL was examined under electron scanning microscope, (Figure 
3.42), differences of the surface morphology between amoxicillin tri-hydrate and AMSL 
is evident. AMSL appears to be more spherical with an average particle size of 0,32 μm 
compared to amoxicillin tri-hydrate with an average particle size of 2,95 μm. 
                     
(a)         (b) 
Figure 3.42: SEM pictures of (a) amoxicillin tri-hydrate and (b) AMSL. 
 
Comment: 
A similar co-crystal was produced using the neat grinding technique. Hence, the 
solvent did not play a significant role in the co-crystal formation. 
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3.3.6 Amoxicillin tri-hydrate - succinic acid co-crystal. 
 
 Succinic acid 
 
Succinic acid (butanedioic acid) has two carboxylic acid groups (diprotic) within its 
structure (Table 3.1). These carboxyl groups (COOH) are most suited hydrogen bond 
donors that play a major role in co-crystal formation. 
 AMSC 
Preparation: 
The co-crystal was prepared by dry grinding of amoxicillin tri-hydrate with succinic 
acid in a stoichiometric ratio of 1:1. The grinding was conducted manually for 30 
minutes at room temperature.  
 
Analytical analysis of AMSC: 
 
A. Thermal analysis: 
 
DSC 
The DSC thermogram of AMSC (Figure 3.43) showed a broad peak in the range of 68-
110 °C which represented the water loss of the amoxicillin tri-hydrate.  The melt of the 
sample occurred between 131-141 °C and decomposition of the sample commenced 
from 170 °C. 
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Figure 3.43: DSC thermogram of AMSC. 
 
 
 
 HSM 
 
The AMSC thermal investigation under HSM (Figure 3.44) showed release of bubbles 
at 85 °C and the sample started to melt at 130 °C. The melt was also complemented 
with a few bubbles (either continuation of water of amoxicillin tri-hydrate being 
released or fragmentation of co-crystal during melting stage). 
                 (a) 92°C                                                  (b)130°C 
           
   Figure 3.44: HSM pictures of  (a) Release of solvent and (b) AMSC melt. 
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TGA 
 
TGA analysis of AMSC indicated a small amount of mass loss equalling to 0.009% 
(n=0.86) (Figure 3.45). 
 
Figure 3.45: TGA analysis of AMSC. 
 
 
 
B. Spectroscopic analysis 
 
FTIR spectroscopy 
The AMSC IR spectrum kept the amoxicillin tri-hydrate spectrum with shifts for 
(CN,CN)+(NH,CH,CH) from 1217.80 cm-1 to 1200.94cm-1 and the shift within the 
succinic acid spectrum for a OH group was from1409.20 cm-1 to 1417.99 cm-1 (Figure 
3.47 and Table 3.11). 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 600 515.0
cm-1
%T 
a
b
c
2970.29
1774.06
1685.10
1614.98
1577.22
1519.03
1483.80
1451.25
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1177.54
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1021.31
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847.43
837.93
802.87
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695.56
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554.91
520.06
2969.92
1772.26
1684.81
1615.28
1576.40
1519.29
1481.52
1450.62
1396.00
1378.30
1361.21
1328.00
1312.64
1282.43
1247.78
1217.80
1196.22
1177.72
1144.28
1119.93
1076.63
1021.01
1002.67
986.18
922.37
872.94
847.67
837.79
732.85
695.33
2929.76 2625.89
2532.40
1680.31
1409.20
1305.32
1196.18
1175.58 800.17
 
Figure 3.46: IR spectra of (a) AMSC, (b) Amoxicillin tri-hydrate and (c) 
Succinic acid. 
 
 
Figure 3.47: Possible interaction sites between amoxicillin tri-hydrate and 
succinic acid to form AMSC. 
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Table 3.11: Peak shifts of AMSC FTIR spectrum. 
AMSC  Amoxicillin tri-hydrate frequency 
band and functional group 
Succinic acid 
frequency band and 
functional group 
1200.94 1217.80 
(C5N10,C3N1)+(N10H,C5H,C2H) 
- 
1417.99 - 1409.20 (C-OH) 
 
H1-NMR analysis 
NMR showed a homogenous preparation and estimated that the two components are 
bound together in a 2:1 ratio. AMSC spectrum is attached in Appendix C. 
  
C. PXRD 
 
AMSC has a distinctive PXRD pattern (Figure 3.48) compared to the parent 
compounds. Clear differences occurred at 16°, 18.9°, 23.7°, 25.5°, 29°, 35.1°, 36.6°, 37.8° 
and 38.4° 2θ peaks indicating a new multicomponent crystalline system between 
amoxicillin tri-hydrate and succinic acid. 
 
 
Figure 3.48: PXRD pattern of AMSC, amoxicillin tri-hydrate and succinic acid. 
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D. SEM 
Figure 3.49 indicate the shape comparison of amoxicillin tri-hydrate and AMSC under 
50 magnifications. AMSC is characterized by a rectangular shaped crystal with a 
particle size of 6.8 μm compared to amoxicillin tri-hydrate having a similar rectangular 
shape but with a smaller average particle size of 2,95 μm. 
               
(a)         (b) 
  Figure 3.45 SEM pictures of (a) amoxicillin tri-hydrate and (b) AMSC. 
Note: 
The same co-crystal with the same properties was produced using 1:0.7 ratios 
 
3.3.7  Amoxicillin tri-hydrate-benzoic anhydride co-crystal. 
 Benzoic anhydride 
 It is a benzoic acid derivative (Table 3.1) produced by dehydration of benzoic acid and 
is used in food as a preservative. The two carbonyl groups included within the structure 
are targeted as opportunities to form non-covalent bonds with amoxicillin tri-hydrate. 
AMB 
Preparation: 
The co-crystal was prepared by grinding amoxicillin tri-hydrate with benzoic 
anhydride in a 1:1 stoichiometric ratio and two drops of (0.1 N) HCl          solution was 
added drop-wise to the powders. The grinding was carried out manually in a mortar 
with a pestle at 25 °C for 30 minutes. 
 
 
 
 
 108 
 
 Analytical analysis of AMB: 
A. Thermal analysis 
 
DSC 
 
One sharp peak between 66-100 °C on the DSC thermogram (Figure 3.46) of AMB 
indicates the co-crystal melt which overlapped with the water loss peak of amoxicillin 
tri-hydrate followed immediately by degradation 
 
Figure 3.46: DSC thermogram of AMB. 
 
 
HSM         
 
AMB was investigated under HSM (Figure 3.47). A small amount of AMB was 
scattered on a glass slide and covered with a drop of silicon oil. Between 60-100 °C the 
powder reduced in particle size and bubbling commenced. The melt is very clear at 100 
°C which is between the melt of the parent compounds. Around 120 °C the melt was 
complete and spontaneous bubbling started, indicating decomposition of AMB.  
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(a) 25 °C     (b)100 °C 
       
   (c)  120 °C 
  
Figure 3.47: HSM pictures of AMB, (a) Sample at room temperature, (b) Melt of 
AMB and (c) Start of AMB decomposition 
 
TGA 
No significant mass loss was indicated by the TGA analysis curve of AMB (Figure 
3.48). This confirms the DSC peak and observation under HSM which indicates that the 
fragmentation and melting occurred within the same range of temperature. The slight 
amount of water release was due to the fragmentation of sample particles upon heating. 
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Figure 3.48: TGA analysis of AMB. 
 
 
B. Spectroscopic analysis 
 
FTIR spectroscopy 
FTIR spectra of AMB (Figure 3.49) showed peak shifts for both amoxicillin tri-hydrate 
and benzoic anhydride. The significant shift include the COOH, NH, NH2 , OH groups 
of amoxicillin tri-hydrate and C-O group of benzoic anhydride. 
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Figure 3.49: FTIR spectrum of (a) AMB1, (b) Amoxicillin tri-hydrate and 
(c) Benzoic anhydride. 
 
 
Figure 3.50: Possible interaction sites between amoxicillin tri-hydrate and 
benzoic anhydride. 
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Table 3.25: Peak shifts of AMB FTIR spectrum. 
AMB Amoxicillin tri-hydrate frequency 
band and functional groups 
Benzoic anhydride 
frequency band and 
functional groups  
1211.30 1217.80 (N10H, N19H2)+ (CH) - 
Lost 1196.22 - 
1173.26 1177.72 (CH benzene)+O25H) 
+(CH)+(N19H2) 
- 
1037.99 - 1032.09 (ether C-O) 
705.12 732.85(O13H)+(C8O2H)+CH3+(C7C3) 667.10 (aromatic C-H) 
 
H1-NMR analysis 
H1- NMR indicates a homogenous preparation. The co-crystal estimated to form a 
1:1.4 amoxicillin tri-hydrate to benzoic anhydride ratio. 
 
C. PXRD 
 
AMB PXRD pattern (Figure 3.51) showed differences in the peaks at 15.5°, 17.7°, 
17.9°, 26.5°, 28°, 28.4° and 29.5° compared to the starting material. This was an 
indication and further confirmed that a co-crystal had formed between amoxicillin tri-
hydrate and benzoic anhydride.  
 
 
Figure 3.51: PXRD patterns of AMB, amoxicillin tri-hydrate and benzoic 
anhydride. 
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D. SEM 
The AMB morphology was compared to the amoxicillin tri-hydrate morphology 
(Figure 3.52). AMB was characterized with long needle-like crystals with an average 
particle size of 0,81 μm compared to amoxicillin tri-hydrate with an average particle 
size of 2,95 μm. 
 
                       
(a)               (b) 
Figure 3.52 SEM pictures of (a) amoxicillin tri-hydrate and (b) AMB. 
 
Comment: 
Eight co-crystals of amoxicillin tri-hydrate with possibly different properties were 
produced using the grinding technique. The co-crystals produced could enhance the 
physical or chemical properties of amoxicillin tri-hydrate. For this study, dissolution 
testing was investigated to determine whether the co-crystal had a superior dissolution 
profile over the pure amoxicillin tri-hydrate. 
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3.3.8 Amorphous form of amoxicillin- L-tartaric acid  co-crystal (AMP) 
Preparation: 
An amorphous form of amoxicillin tri-hydrate was obtained by grinding amoxicillin tri-
hydrate with L-tartaric acid in the presence of methanol as a solvent.  The two 
components were mixed in a 1:1 ratio. The methanol was added drop-wise to the 
mixture during the grinding procedure. Manual grinding for 30 minutes at room 
temperature was carried out. 
Analytical analysis of the AMP: 
A. Thermal analysis 
 
DSC 
The melt of the sample was indicated clearly by a very broad peak in the range of 44-
130 °C (Figure 3.53). 
 
Figure 3.53: DSC thermogram of AMP. 
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HSM 
 
From 85 °C until 120 °C bubbles where released (which might indicate to the presence 
of the solvent) without any significant melt. At 125 °C the melt started and completed 
at 160 °C. 
 
(a)  85 °C     (b) 130 °C  
                                    
Figure 3.54: illustrate (a) Solvent release from AMP and (b) Melt of AMP.  
 
TGA 
Figure 3.55 shows the thermal behaviour of AMP. The TGA data showed a very small 
amount of mass loss between the temperature range of 30-100 °C. 
 
 Figure 3.55: TGA analysis of AMP. 
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B. Spectroscopic analysis 
 
FTIR spectroscopy  
The AMP IR spectrum shows a significant decrease of the peak intensity compared 
to the amoxicillin tri-hydrate spectra. The majority of the peaks are slightly shifted 
to a lower frequency and some peaks even disappeared. Both intensity reduction and 
peak disappearance indicates alteration of crystalline organization. 33 
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Figure 3.56: FTIR spectra of (a) AMP, (b) Amoxicillin tri-hydrate and 
 (c) L-tartaric acid. 
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H1-NMR analysis 
 
The NMR spectrum assures a homogeneous preparation of AMP, the spectrum is 
attached in Appendix C. Since tartaric acid contains the two asymmetric centres, this 
makes it challenging to determine the ratio of the L-tartaric acid present in the sample. 
DSC was once again applied as a predictor for the ratios. Since both parent compounds 
were not present on the DSC thermogram, the ratio is predicted to be 1:1.  
 
C. PXRD 
The diffraction pattern of the sample (Figure 3.57) lacks high intense peaks that 
characterize crystalline substances.  The pattern was characterized with broad diffuse 
peaks which concludes an  amorphous substance. 
 
 
Figure 3.57: PXRD pattern of AMP, amoxicillin tri-hydrate and L-tartaric 
acid. 
 
 
D. SEM 
 
SEM pictures under different magnification showed a difference in the arrangement and 
the shape of the particles. (Figure 3.58) Amoxicillin tri-hydrate is characterized with 
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long rectangular shaped crystals where AMP was characterized with semi-round 
particles with a particle size of 0.71 μm.  
                    
(a)                                  (b) 
Figure 3.58: SEM pictures of (a) amoxicillin tri-hydrate and (b) AMP. 
 
 
Comment: 
An amorphous form of amoxicillin tri-hydrate-L-tartaric acid co-crystal was produced 
by the grinding procedure. When the experiment was conducted with amoxicillin tri-
hydrate alone the outcome was negative. The new form has a very low melting point as 
indicated by the thermal analysis techniques (DSC and HSM).  
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CHAPTER 4 
DISSOLUTION TESTING  
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CHAPTER 4: Will focus on the pharmaceutical dissolution evaluation of the 
different forms of amoxicillin tri-hydrate produced. The dissolution test was 
performed for each sample over a 60 minute interval, UV/Vis spectrophotometry 
was used to read the absorbance of sample solutions at a wavelength of 272 nm. 
4.1 Introduction 
Dissolution is a process used to access and evaluate the release of the drug from the 
drug formulation. The dissolution profile of drug substances is a very important aspect 
of the quality control of new formulations. Dissolution is defined as the dynamic 
process by which the amount of drug substances goes into solution per unit time under 
consistent conditions.1 Dissolution testing is the analytical technique used and  
considered as a suitable method for evaluation of novel APIs and drug formulation.1 It 
provides  useful information on the in vitro release of drug substances.2 
In pre-formulation, dissolution testing is used routinely for the evaluation of the 
physicochemical properties of the drug substances to serve as an indicator for the 
proper selection of the solid form of the drug.1 The dissolution process comprises of two 
main stages. The first stage is the disintegration stage (liberation of the drug from the 
formulation) followed by solubilisation of the drug substances in the dissolution 
medium.3 The solubility of the drug, as well as the surface area from which the drug 
dissolved plays a major role and affects the dissolution of the drug substances.4  
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4.2 Dissolution testing 
 
Simple and economic dissolution testing can be utilized for drug development, drug   
quality and drug performance.5 In this study, the methodology and specification of 
dissolution testing was carried out according to the Unites States Pharmacopoeia 
(USP).6 The dissolution test of all forms was carried out using the rotating basket 
method at 37 °C as described in Chapter 2. The result of the dissolution analysis is 
shown in Figure 4.1.  
USP 36 states that not less than 80% dissolution is required after 60 minutes and this 
must be met by each capsule. The different forms illustrate different dissolution results 
(Table 4.1 and Figure 4.1). The amorphous co-crystal showed a significant increase in 
the dissolution profile compared to the hydrated amoxicillin co-crystals. This might 
enhance the bioavailability of the drug. Amoxicillin tri-hydrate-nicotinamide (AMN), 
amoxicillin tri-hydrate-saccharin2 (AMS2) and amoxicillin tri-hydrate-benzoic 
anhydride (AMB) dissolution profile was significantly high showing a very similar 
profile to amoxicillin tri-hydrate. AMN, however had a slightly higher average 
percentage dissolved (95%) compared to amoxicillin tri-hydrate (92.25%).  
Co-crystallization of amoxicillin tri-hydrate with salicylic acid (AMSL), saccharin 
(AMS1) and oxalic acid di-hydrate (AMO) failed the USP pharmacopoeial standard 
with an average of 78.1%, 74.3% and 58.6% amoxicillin tri-hydrate dissolved 
respectively after 60 minutes. 
Co-crystallization of amoxicillin tri-hydrate with succinic acid (AMSC) showed a very 
poor dissolution profile of 15%, whereas co-crystallization of amoxicillin tri-hydrate 
with L-tartaric acid (AMP) showed the best profile of 121.4%.  
When the % dissolution profile is greater than 100%, the results are questionable, 
however, in this instance, we explain the result firstly, by the fact that all the analytical 
data illustrates an amorphous compound. An amorphous compound is known to have a 
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significantly better solubility and dissolution profile than a crystalline compound. 
Secondly, the co-former could have been detected by the UV spectrophotometer at 272 
nm. L-tartaric acid can be detected by UV-Vis since it contains double bonds. Finally, 
the high % dissolution result could also be rationalised by an experimental error if the 
standard curve used to analyse the data did not fall within the limits of the data 
presented then the data could be miscalculated and be misrepresented.  
 
Table 4.1: Percentage dissolution of amoxicillin tri-hydrate versus co-crystals 
produced over 60 minutes in water (pH 6.8 at 37°C) 
Vessel  Amoxi- 
cillin  
tri-hydrate 
AMS1 AMS2 AMTd AMSL AMN AMSC AMB AMP AMO 
1 87.9 82.2 93.3 55.1 88.2 93.6 13.2 93.9 87.9 70.4 
2 87.5 75.6 95.3 47.4 67.8 90.9 14.5 88.6 125.6 52.2 
3 79.2 83.7 90.5 43.5 78.3 97.0 18.8 89.3 141.5 58.6 
4 85.9 58.3 87.1 23.2 87.7 98.7 21.8 74.3 116.4 58.8 
5 109.2 75.3 95.0 28.3 79.9 96.2 12.3 76.0 133.3 55.2 
6 103.8 70.4 79.8 38.8 66.2 93.7 9.9 93.2 124.1 56.7 
Ave. % 92.25 74.3 90.1 39.3 78.1 95.0 15.0 85.8 121.4 58.6 
 
 
Figure 4.1: A comparative bar graph of % dissolution in each vessel and the % 
average value for amoxicillin tri-hydrate vs. co-crystals of amoxicillin. 
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Based on the dissolution profile of each amoxicillin co-crystal, we can conclude that the co-
former definitely impacts the dissolution rate of amoxicillin. Choosing the most appropriate 
co-former for the desired dissolution rate may now be effected. Other desired characteristics 
that may be investigated include flow properties of the co-crystal granules, antibacterial 
activity of amoxicillin (if an enhanced dissolution profile is recognized compared to parent 
compound) and stability of amoxicillin as a co-crystal. 
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CHAPTER 5 
CONCLUSION AND 
RECOMMENDATION 
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CHAPTER 5: Presents concluding remarks of the study as well as 
recommendations for future work 
5.1 Conclusion 
Polymorphism and co-crystallization are two useful drug modification strategies used in 
the pharmaceutical industry today. These two processes were evaluated for the specific 
β-lactam penicillin type antibiotic, amoxicillin tri-hydrate. 
Polymorphism experimentation outcomes were not significant, whereas new co-crystal 
materials were synthesised using the grinding and solvent assisted grinding techniques 
with several co-formers. Each co-crystal displays a unique physical and chemical 
property. Table 5.1 shows the comparative analysis of a few of these properties.  
Table 5.1: Comparative analysis of amoxicillin tri-hydrate co-crystals with 
selected co-formers 
 
M.p  of 
compound 
(°C) 
Mp of co-
crystal 
(°C) 
Particle 
size (μm) 
% Water 
loss 
% Ave 
dissolution 
Ratio 
Interaction 
sites of 
amoxicillin 
tri-hydrate 
Interaction 
sites of co-
former 
Amox. 
3H2O 
186 - 0.81 13% 92.3 - - - 
AMB 40 66-100 0.81 0 85.8 1:1 
COOH+NH+ 
OH 
 
AMO 101-102 146 0.21 1.5 58.6 1:1 
H2O+CO+ 
NH2+OH 
COOH+ 
H2O 
AMN 128-131 144-165 7.15 10.3 95 1:1 H2O NH2 
AMSL 158-161 107-115 0.32 0 78.1 1:1 H2O+OH C=O 
AMTd 171-174 128 13.2 11.11 39.9 1:1 COOH COOH 
AMP 174 85 0.71 ---- 128 1:1 ---- ---- 
AMSC 184 131-141 6.8 0.009 15.6 1:1 NH OH 
AMS1 228 152 8.2 1.78 74.3 1:1 H2O+OH C=O 
AMS2 228 147 9.3 1.63 90.1 1:0.7 
H2O+OH+ 
CO+NH 
C=O 
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Figure 5.1 illustrates the co-crystal melting point versus the co-former melting point. It 
is evident that as the co-former m.p. increases, the co-crystal m.p. increases. It is thus 
deduced that amoxicillin could possibly be investigated for further stability studies 
employing co-formers that may increase its melting point profile and hence possibly 
improve its stability. 
 
Figure 5.1: Co-crystal melting point versus co-former melting point. 
 
The average percentage dissolution versus particle size of co-crystals in Figure 5.2 
illustrates that as the particles size increases, the % dissolution initially increases, 
then decreases significantly, then increases again. This indicates that there is no 
direct relationship between particle size and the dissolution profile and that other 
variables are definitely impacting on the dissolution profile. Other variables that may 
be considered in this instance are variables such as the pKa values of the individual 
co-forming ingredients (Table 5.2), wettability of granules and assurance of an equal 
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particle size, since size variation can impact solubility significantly. All the dissolution 
profiles were conducted in distilled water which has a pH=6.8 and all co-formers had 
a pKa value below 7. 
 
Figure 5.2: Average percentage dissolution versus particle size of co-crystals. 
Table 5.2: PKa values of amoxicillin tri-hydrate co-crystals and selected co-
formers vs. % average dissolution profile of co-crystals produced. 
 PKa 
% Ave dissolution 
Amoxicillin tri-hydrate 3H2O 
2.67, 7.11, 9.55 
  
AMS1 2.32 74.3 
AMS2 2.32 90.1 
AMO 1.25, 4.14 58.6 
AMTd 2.95, 4.25 39.9 
AMN 3.35 95 
AMSl 2.98 78.1 
AMSC 4.2, 5.6 15.6 
AMB 4.2 85.8 
AMP 2.95, 4.25 128 
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5.2 Future Work 
Even though this study‟s initial focus was to create the formation between amoxicillin 
tri-hydrate and clavulanic acid co-crystal, which did not come to fruition, various other 
co-formers were investigated. The pharmaceutical department at UWC will continue to 
pursue these experiments due to the synergistic effect of the two compounds when 
combined for its therapeutic purposes.  
The laboratory work completed thus far indicates that the dissolution profile of 
amoxicillin tri-hydrate is affected depending on the co-former chosen and possibly 
enhanced as well.  Antimicrobial assessment of these forms is recommended to compare 
the microbial activity of pure amoxicillin tri-hydrate to the derivatized forms if the 
dissolution profiles are significantly different. Structure elucidation by Rietveld 
refinement is also recommended using the PXRD data and the complementary DSC, 
TGA, HSM, NMR, FTIR and SEM data. 
 
Few peaks occur in the powder pattern in high symmetry crystal systems. The peaks 
are typically well-resolved and it is possible to measure their positions and intensities 
with accuracy, then index the reflections and solve the single crystal structure. Larger 
and less symmetrical structures have far more peak overlap and it is difficult to 
accurately extract the peak intensities. Rietveld analysis is a technique that has been 
developed for solving/refining crystal structures from powder diffraction data. It 
involves an interpretation of the peak positions and intensities. The large amount of 
peak overlap requires analysing the overall line profiles, where each allowed reflection 
(peak) is given convolution of a Gaussian/lorentzian line shape. The peaks are allowed 
to overlap to form an overall line profile. 
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Rietveld Method – Powder Diffraction 
The Rietveld method can be used to refine („solve‟) a crystal structure. If a trial 
structure is known, from an isostructural compound or hypothetical model, the crystal 
structure may be refined. The method takes a trial structure, calculates a powder 
diffraction profile and compares it to the measured profile. The trial structure is 
modified by changing various refinable parameters, including atomic positions, 
thermal parameters, site occupancies, peak shape parameters, etc., until a best-fit match 
is obtained with the measured pattern. 
 
Difference pattern 
Observed data 
Calculated profile 
Allowed Bragg reflection 
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Final Remarks 
A strong attempt was made to produce single crystals of the products formed however 
we were unsuccessful due to the nature of the stability characteristics of amoxicillin. 
Given this restriction, we were successful in producing convincing evidence of the co-
crystallization of amoxicillin tri-hydrate. The techniques used to analyse physical and 
chemical properties were; DSC, HSM, TGA, FTIR, NMR, SEM and PXRD. Single X-
ray diffraction would have been considered most superior and convincing in 
establishing the chemical properties of our products but given the limitations the 
following suggestion is made for a further study to strategically elucidate the structure 
using the data already assimilated and the Rietveld method explained above: 
To elucidate the structures using the DSC, HSM, TGA, FTIR, NMR, SEM and PXRD 
results obtained: 
 NMR and DSC would confirm the ratio in of the starting material. 
 TGA would indicate the presence of solvent and number of mole present per 
complex calculated. 
 FTIR alluded to the possible bonding sites by either shift in peaks or decrease in 
intensity of peaks. 
 Finally, the PXRD pattern could then be matched using the Rietveld method 
explained. 
 
Finally, a clear attempt was made to improve the solubility, dissolution and stability profile 
of amoxicillin tri-hydrate by co-crystallization. There is definite evidence that the current 
study will provide a solid framework for future work in this regard. 
 
--------------- 
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APPENDIX A 
Experiments 
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Appendix A: List of the polymorphism and co-crystallization experiments of 
amoxicillin tri-hydrate conducted. Modifications either in ratio, temperature or 
time were applied and only the most relevant were included in the study. 
When reading tables, the following abbreviations should be noted:  
H2O - Water 
HCl -  Hydrochoric acid 
DMSO - Dimethyl sulfoxide 
MeOH - Methanol 
NaOH - Sodium hydoxide 
SAG - Solvent assisted grinding 
VD - vapour diffusion 
SEV - Solvent evaporation 
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1. Experiment of polymorph production 
 
       Recrystallization of amoxicillin tri-hydrate from solution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Solvent Temperature (°C) 
1 H2O 90 
2 H2O 50,80 
3  Methanol 25,50 
4 NaOH 25,50,90 
5 Ethanol 25,50,68 
6 HCL solution 25,50,90 
7 Acetone 25,50,46 
8 Phosphate buffer 25,50,90 
9 Ethanol+DMSO 25,50,68 
10 Propanol+DMSO 25,50,87 
11 Acetone+DMSO 25,50,46 
12 Ethylacetate+DMSO 25,50,67 
13 1,4-dioaxne+H2O 25,50,90 
14 Chloroform+MeOH 25,50 
15 Diethylether+DMSO 25,50 
16 Benzyl alcohol+H2O 25,50,100 
17 Propylene glycol+MeOH 25,50,100 
18 Ethylene glycol+NaOH 25,50,100 
19 Toluene+DMSO 25,50,9 
20 MeOH+NaOH 25,50,100 
21 MeOH+HCL 25,50 
22 NaOH+propanol 25,50,87 
23 Propanol+HCL 25,50,87 
24 Benzyl alcohol 25,50 
25 NaOH+acetone 25,50 
26 NaOH+water 25,50 
27 Benzyl alcohol +methanol 25,50,100 
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       Grinding of Amoxicillin tri-hydrate (25 °C) 
sample method Solvent Time(minutes) 
1 Dry grinding None 30 
2 Dry grinding None 40 
3 SAG Propanol 40 
4 SAG Water 40 
5 SAG NaOH solution 40 
6 SAG Methanol 30 
7 SAG Ethanol 30 
8 SAG Propanol 30 
9 SAG Di-ethyl ether 30 
10 SAG HCL solution 30 
11 SAG Butanol 30 
12 SAG DMSO 30 
13 SAG Benzyl alcohol 30 
14 SAG Ethyl acetate 30 
15 SAG Acetone 30 
16 SAG Phosphate buffer 30 
 
            Vapour diffusion (VD) (25 °C) 
Sample Solvent 1 Solvent 2 Result 
1 Acetone Chloroform Negative  
2 Methanol Chloroform Negative  
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2. Experiments for co-crystal production: 
Amoxicillin tri-hydrate and saccharine 
Sample Ratio Solvent Time/min. Method Result 
1 1:1 Water - SEV negative 
2 1:1 Methanol - SEV negative 
3 1:0.7 Methanol - SEV Negative 
4 1:1 Acetone 30 SAG  
5 1:1 Acetone 30 Heating Positive 
6 1:0.7 Acetone 30 SAG negative 
7 1:1 None 30 Dry 
grinding 
Negative 
8 1:0.7 None 30 Dry 
grinding 
Negative 
9 1:0.7 Ethanol 96 % - SEV Negative 
10 1:0.7 Butanol - SEV Negative 
11 1:0.7 butanol +methanol - SEV Negative 
12 1:1 DMSO - SEV Negative 
13 1:0.7 DMSO - SEV Negative 
14 1:0.7 Water 30 SAG Negative 
15 1:1 Water 30 SAG Negative 
16 1:1 NaOH solution - SEV Negative 
17 1:1 NaOH solution 30 Heating Negative 
18 1:0.7 NaOH solution 30 SAG Negative 
19 1:1 NaOH solution 30 SAG Negative 
20 1:1 NaOH solution 30 Heating Negative 
21 1:0.7 NaOH solution 30 Heating Negative 
22 1:0.7 Water 30 Heating Negative 
23 1:0.7 HCL 
solution+water+methanol 
- SEV Negative 
24 1:0.7 HCL solution 30 SAG Negative 
25 1:1 Methanol/chloroform - VD Negative 
26 1:0.7 Methanol/chloroform - VD Negative 
27 1:1 NaOH /chloroform - VD Negative 
28 1:1 HCl solution + 
propanol+DMSO 
- SEV Negative 
29 1:1 HCL solution 30 SAG Negative 
30 1:1 Phosphate buffer - SEV Negative 
31 1:1 Phosphate buffer 30 SAG Negative 
32 1:1 Phosphate buffer 30 Heating Positive 
33 1:0.5 Phosphate buffer 30 Heating Positive 
34 1:1 Water+ NaOH solution 30 Heating Negative 
35 1:1 Acetone - SEV Negative 
36 1:1 Acetone+ NaOH - SEV Negative 
37 1:0.7 Acetone+ NaOH - SEV Negative 
38 1:0.7 Acetone+HCL - SEV Negative 
39 1:1 Acetone+Phosphate buffer - SEV Negative 
40 1:1 Acetone+water+ NaOH - SEV Negative 
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Amoxicillin tri-hydrate and nicotinamide. 
Sample Ratio Solvent Time Method Result 
1 1:1 None 30 dry 
grinding 
Negative 
2 1:0.7 None 30 dry 
grinding 
Negative 
3 1:1 Methanol - SEV Negative 
4 1:0.7 Methanol - SEV Negative 
5 1:1 Water+methanol - SEV Negative 
6 1:1 DMSO +methanol - SEV Negative 
7 1:1 DMSO 30 SAG Negative 
8 1:0.7 Water 30 SAG Negative 
9 1:1 Water 30 SAG Negative 
10 1:1 NaOH - SEV Negative 
11 1:0.5 NaOH - SEV Negative 
12 1:0.5 NaOH - Heating Negative 
13 1:0.7 HCL - SEV Negative 
14 1:1 Methanol/chloroform - VD Negative 
15 1:0.7 NaOH/chloroform - VD Negative 
16 1:1 HCL - SEV Negative 
17 1:0.7 NaOH 30 SAG Negative 
18 1:1 HCL 30 SAG Negative 
19 1:0.7 HCL 30 SAG Negative 
20 1:1 Phosphate buffer - SEV Negative 
21 1:1 Phosphate buffer 30  SAG Positive 
22 1:1 - Phosphate buffer 30 Heating Negative 
23 1:1 Methanol - SEV Negative 
24 1:1 Methanol +water - SEV Negative 
25 1:0.7 Acetone+DMSO - SEV Negative 
26 1:1 Acetone +NaOH - SEV Negative 
27 1:0.7 Acetone +NaOH - SEV Negative 
28 1:1 Acetone+water+DMSO - SEV Negative 
29 1:1 Acetone +HCL solution - SEV Negative 
30 1:0.7 Acetone +HCL solution - SEV Negative 
31 1:1 Acetone +HCL solution - SEV Negative 
32 1:0.7 Acetone +HCL solution - SEV Negative 
33 1:1 Acetone 30 SAG Negative 
34 1:1 Water+methanol - SEV Negative 
35 1:1.5 Water +methanol - SEV Negative 
36 1:1 NaOH solution 30 SAG Negative 
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Amoxicillin tri-hydrate and benzoic anhydride 
Sample Ratio Solvent Time/min Method Result 
1 1:0.7 Methanol - SEV Negative 
2 1:0.7 Methanol+water - SEV Negative 
3 1:1 Actone 
+methanol+water 
- SEV Negative 
4 1:1 Diethyl-ether 
+methanol+water 
- SEV Negative 
5 1:1 Methanol +butanol - SEV Negative 
6 1:0.7 1,4 dioxane +methanol - SEV Negative 
7 1:0.7 None 30 Dry 
grinding 
Negative 
8 1:0.7 Methanol 30 SAG Negative 
9 1:0.7 Water 30 SAG Negative 
10 1:0.7 Acetone 30 SAG Negative 
11 1:0.7 Ethyl acetate+ methanol - SEV Negative 
12 1:0.7 Propanol + methanol - SEV Negative 
13 1:0.7 1,4-dioxane + methanol - SEV Negative 
14 1:0.7 None 30 Dry 
grinding 
Negative 
15 1:0.7 Methanol 30 SAG Negative 
16 1:0.7 Acetone 30 SAG Negative 
17 1:0.7 Ethyl acetate+methanol - SEV Negative 
18 1:0.7 Propanol+methanol - SEV Negative 
19 1:1 Water+methanol - SEV Negative 
20 1:1 Methanol - SEV Negative 
21 1:1 Propanol +water - SEV Negative 
22 1:1 None 30 Dry 
grinding 
Negative 
23 1:1 Acetone 30 SEV Negative 
24 1:1 1.4-dioxane+methanol - SEV Negative 
25 1:1 Diethyl ether - SEV Negative 
26 1:1 Water 30 SAG Negative 
27 1:1 Methanol 30 SAG Negative 
28 1:1 Acetone 30 SAG Negative 
29 1:1 DMSO - SEV Negative 
30 1:0.7 DMSO - SEV Negative 
31 1:0.7 NaOH 
solution+methanol 
- SEV Negative 
32 1:1 NaOH solution + SEV Negative 
33 1:0.7 NaOH solution - Heating Negative 
34 1:1 NaOH solution 30 Heating Negative 
35 1:1 Methanol/chloroform - VD Negative 
36 1:0.7 Methanol/chloroform - VD Negative 
37 1:0.7 NaOH solution 30 SAG Negative 
38 1:1 HCL solution+ propanol - SEV Negative 
39 1:0.7 HCL solution 30 SAG Negative 
40 1:1 HCL solution 30 SAG Positive 
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41 1:1 NaOH solution 30 SAG Negative 
42 1:1 Phosphate 
buffer+DMSO 
30 SEV Negative 
43 1:1 Phosphate buffer 30 SAG Negative 
44 1:1 Phosphate buffer 30 Heating Negative 
45 1:0.7 Phosphate buffer - SEV Negative 
 
Amoxicillin tri-hydrate with maleic acid 
Sample Ratio Solvent Time/min. Method Result 
1 1:0.5 Methanol - SEV Negative 
2 1:0.5 Acetone - SEV - 
3 1:1 Methanol - SEV - 
4 1:0.5 Propanol - SEV - 
5 1:0.5 None 30 Dry 
grinding 
- 
6 1:0.5 Water - SEV - 
7 1:1 Water - SEV - 
8 1:1 None 30 Dry 
grinding 
- 
9 1:1 Acetone - SEV - 
10 1:1 ethanol - SEV - 
11 1:1 Propanol - SEV - 
12 1:1 1.4-dioxane+methanol - SEV - 
13 1:0.5 Butanol+methanol - SEV - 
14 1:0.5 Water 30 SAG - 
15 1:1 DMSO - SEV - 
16 1:0.5 DMSO - SEV - 
17 1:1 Water 30 SAG - 
18 1:0.5 NaOH solution - SEV - 
19 1:1 NaOH solution - SEV - 
20 1:0.5 NaOH solution 30 Heating - 
21 1:1 NaOH solution 30 Heating - 
22 1:0.5 NaOH solution 30 Heating - 
23 1:0.5 Methanol 30 Heating - 
24 1:0.5 Butanol - SEV - 
25 1:0.5 Water - SEV - 
26 1:1 Methanol/chloroform - VD - 
27 1:0.5 Methanol/chloroform - VD - 
28 1:0.5 HCL solution - SEV - 
29 1:1 NaOH solution 30 SAG - 
30 1:0.5 NaOH solution 30 SAG - 
31 1:1 HCL solution 30 SAG - 
32 1:0.5 HCL solution 30 SAG - 
33 1:1 Phosphate buffer - SEV - 
34 1:1 Phosphate buffer 30 SAG - 
35 1:1 Phosphate buffer 30 Heating - 
36 1:1 Acetone +water - SEV - 
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37 1:1 Acetone +NaOH - SEV - 
38 1:1 Acetone+ HCL solution - SEV - 
39 1:1 Acetone +methanol - SEV - 
40 1:1 HCL solution+acetone - SEV - 
41 1:1 Acetone+methanol - SEV - 
42 1:1 Ethanol+acetone - SEV - 
43 1:1 Phosphate buffer+acetone - SEV - 
44 1:1 Benzyl alcohol+acetone - SEV - 
45 1:1 Polyethylene 
glycol+acetone 
- SEV - 
46 0.5:1 Polyethylene 
glycol+acetone 
30 Dry 
grinding 
- 
 
Amoxicillin tri-hydrate with oxalic acid di-hydrate. 
Sample Ratio Solvent Time/min. Method Result 
1 1:0.5 None  30 Dry grinding Negative 
2 1:1 None 30 Dry grinding - 
3 1:1 Methanol - SEV - 
4 1:0.5 Methanol - SEV - 
5 1:1 DMSO - SEV - 
6 1:0.5 DMSO - SEV - 
7 1:0.5 Water 30 SAG - 
8 1:1 Methanol 30 SAG - 
9 1:0.5 Methanol 30 SAG - 
10 1:0.5 NaOH solution - SEV - 
11 1:1 NaOH solution 30 SEV - 
12 1:0.5 NaOH solution 30 Heating - 
13 1:1 NaOH solution 30 Heating - 
14 1:1 HCL +NaOH solution - SEV - 
15 1:1 Methanol/chloroform - VD - 
16 1:0.5 Methanol/chloroform - VD - 
17 1:0.5 HCL solution - SEV - 
18 1:1 HCL solution 3 SAG - 
19 1:0.5 HCL solution 30 SAG - 
20 1:0.5 NaOH solution 30 SAG - 
21 1:1 Phosphate buffer - SEV - 
22 1:1 Phosphate buffer 30 SAG - 
23 1:1 Acetone 30 SAG Positive 
24 1:1 NaOH solution+acetone - SEV Negative 
25 1:1 NaOH solution+HCL - SEV - 
26 1:1 NaOH solution+water - SEV - 
27 1:1 NaOH solution+methanol - SEV - 
28 1:1 Methanol+ethanol - SEV - 
29 1:1 NaOH solution 30 Heating - 
30 1:0.5 Methanol 30 Heating - 
31 1:1 1.4-dioxane+acetone - SEV - 
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Amoxicillin tri-hydrate with citric acid monohydrate 
Sample Ratio Solvent Time/min. Method Result 
1 1:1 1.4-dioxane+acetone 30 SAG Negative 
2 1:0.5 1.4-dioxane+acetone 30 SAG - 
3 1:1 Methanol - SEV - 
4 1:1 Acetone - SEV - 
5 1:0.5 Water 30 SAG - 
6 1:1 Water - SEV - 
7 1:1 Ethanol 30 SAG - 
8 1:0.5 Methanol 30 SAG - 
9 1:1 Methanol 30 Heating - 
10 1:05 Methanol/chloroform - VD - 
11 1:1 Methanol/chloroform - VD - 
12 1:1 Water|+methanol - SEV - 
13 1:1 NaOH - SEV - 
14 1:1 HCL solution+acetone - SEV - 
15 1:1 NaOH solution 30 SAG - 
16 1:0.5 NaOH solution 30 SAG - 
17 1:1 HCL solution 30 SAG - 
18 1:1 DMSO - SEV - 
19 1:0.5 DMSO - SEV - 
20 1:1 Water 30 SAG - 
21 1:1 Acetone 30 heating - 
22 1:1 NaOH solution 30 heating - 
23 1:0.5 HCL solution 30 SAG - 
24 1:0.5 NaOH solution 30 SAG - 
25 1:1 Phosphate buffer - SEV - 
26 1:1 Phosphate buffer 30 SAG - 
27 1:0.5 Phosphate buffer 30 SAG - 
28 1:1 Phosphate buffer+acetone - SEV - 
29 1:1 Methanol+ethanol - SEV - 
30 1:1 Ethanol 30 SAG - 
 
Amoxicillin tri-hydrate with L-aspartic acid  
Sample Ratio Solvent Time/min. Method Result 
1 1:1 Water - SEV Negative 
2 1:0.5 Methanol - SEV - 
3 1:1 Methanol+acetone - SEV - 
4 1:1 Acetone - SEV - 
5 1:1 Ethanol - SEV - 
6 1:0.5 Water - SEV - 
7 1:1 Ethyl acetate - SEV - 
8 1:0.5 Methanol - SEV - 
9 1:1 Water 30 SAG - 
10 1:1 Methanol 30 SAG - 
11 1:1 Ethanol 30 SAG - 
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12 1:0.5 Acetone 30 SEV - 
13 1:1 Phosphate buffer 30 SAG - 
14 1:1 Phosphate buffer - SEV - 
15 1:0.5 NaOH solution - SEV - 
16 1:1 HCL solution   - 
17 1:0.5 HCL solution 30  - 
18 1:1 HCL solution - SEV - 
19 1:1 Methanol/chloroform - VD - 
20 1:0.5 Methanol/chloroform - VD - 
21 1:1 Methanol/chloroform 30 heating - 
22 1:1 Water   - 
23 1:1 Ethyl acetate+methanol 30 Heating -- 
24 1:0.5 Methanol - SEV - 
25 1:1 Methanol+water 30 SAG -- 
26 1:1 Methanol+water - SEV - 
27 1:0.5 None 30 Dry 
grinding 
- 
28 1:1 None 30 Dry 
grinding  
- 
29 1:0.5 NaOH solution 30 heating - 
 
Amoxicillin tri-hydrate with stearic acid  
Sample Ratio Solvent Time/min. Method Result 
1 1:1 Water 30 SAG Negative 
2 1:1 Water 30 SAG - 
3 1:1 Methanol - SEV - 
4 1:0.5 Acetone - SEV - 
5 1:1 Ethanol - SEV - 
6 1:0.5 Water 30 SAG - 
7 1:0.5 DMSO - SEV - 
8 1:0.5 Methanol - SEV - 
9 1:1 Acetone+methanol - SEV - 
10 1:0.5 Methanol 30 SAG - 
11 1:1 Acetone 30 SAG - 
12 1:0.5 Acetone 30 SEV - 
13 1:0.5 Benzyl alcohol - SEV - 
14 1:1 NaOH solution - SEV - 
15 1:0.5 NaOH solution - SEV - 
16 1:1 HCL solution 30 SAG -- 
17 1:0.5 HCL solution 30 SAG - 
18 1:1 None 30 Dry 
grinding 
- 
19 1:0.5 None 30 Dry 
grinding 
- 
20 1:1 Methanol/chloroform - VD - 
21 1:0.5 Methanol/chloroform - VD - 
22 1:1 Methanol/chloroform 30 heating - 
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23 1:1 Acetone 30 heating -- 
24 1:1 NaOH 30 Heating - 
25 1:2 Acetone 30 SAG - 
            
         Amoxicillin tri-hydrate with L-tartaric acid 
Sample Ratio Solvent Time Method Result 
1 1:1 None 30 Dry grinding Negative 
2 1:0.5 None 30 Dry grinding - 
3 1:1 Water 30 SAG - 
4 1:0.5 Water 30 SAG - 
5 1:1.5 Water 30 SAG - 
6 1:1 Methanol 30 SEV - 
7 1:0.5 Acetone 30 SEV - 
8 1:0.5 Methanol 30 SEV - 
9 1:1 DMSO - SEV - 
10 1:0.5 DMSO - SEV - 
11 1:2 Water 30 SAG - 
12 1:1 NaOH - SEV - 
13 1:1 NaOH - Heating - 
14 1:1 HCL solution - SEV - 
15 1:1 Methanol/acetone - VD - 
16 1:1 Methanol/chloroform - VD - 
17 1:0.5 Methanol/chloroform - VD - 
18 1:0.5 HCL solution - SEV -- 
19 1:0.5 HCL solution - SAG - 
20 1:1 HCL solution - SAG - 
21 1:1 NaOH solution - SAG - 
22 1:1 Phosphate buffer - SEV - 
23 1:2 NaOH solution - SAG - 
24 1:0.5 NaOH solution 30 heating - 
25 1:1 HCL solution 30 heating - 
26 1:1 Water 30 heating - 
27 1:1 Methanol 30 heating - 
28 1:1 HCL solution 30 heating - 
29 1:2 None 30 Dry grinding - 
30 1:2 Methanol - SEV - 
31 1:2 Acetone - SEV - 
32 1:2 NaOH - SEV - 
33 1:1 Phosphate buffer  - SEV - 
34 1:0.5 Phosphate buffer - SEV - 
35 1:1 Phosphate buffer 30 SAG - 
36 1:1 Methanol 30 SAG Positive 
37 1:0.5 Phosphate 
buffer+methanol 
- SEV Negative 
 
 
 
 
 
 
146 
 
 Amoxicillin tri-hydrate with D-tartaric acid 
Sample Ratio Solvent Time/min. Method Result 
1 1:1 None 30 Dry 
grinding 
Negative 
2 1:1 Water 30 SAG - 
3 1:0.5 None 30 Dry 
grinding 
- 
4 1:1 Acetone 30 SAG - 
5 1:1 Methanol 30 SAG - 
6 1:0.7 NaOH 30 SAG - 
7 1:0.5 NaOH 30 SAG - 
8 1:1 HCL 30 SAG - 
9 1:0.5 HCL 30 SAG - 
10 1:1 Ethanol 30 SAG - 
11 1:0.5 Water 30 SAG - 
12 1:1 Water - SEV - 
13 1:0.5 Water - SEV - 
14 1:1 Methanol - SEV - 
15 1:0.5 Methanol - SEV - 
16 1:1 Acetone - SEV - 
17 1:0.7 Acetone - SEV - 
18 1:1 NaOH - SEV - 
19 1:1 NaOH+water - SEV - 
20 1:0.5 NaOH+water - SEV - 
21 1:1 Acetone+water - SEV - 
22 1:1 HCL  - SEV - 
23 1:0.5 HCL - SEV - 
24 1:0.5 Acetone +methanol - SEV - 
25 1:1 NaOH 30 heating - 
26 1:1 Water 30 heating - 
27 1:0.5 Water 30 heating - 
28 1:1 HCL 30 heating - 
29 1:1 None 25 heating - 
30 1:1 Acetone/chloroform - VD - 
31 1:0.5 Acetone/chloroform - VD - 
32 2:1 Acetone 30 SAG - 
33 1:1 Phosphate buffer 30 SAG Positive 
34 1:1 Phosphate buffer - SEV Negative 
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Amoxicillin tri-hydrate with salicylic acid 
Sample Ratio Solvent Time Method Result 
1 1:0.7 Methanol - SEV Negative 
2 1:0.7 Methanol+water - SEV - 
3 1:1 Acetone +methanol+water - SEV - 
4 1:1 Diethyl-ether 
+methanol+water 
- SEV - 
5 1:1 Methanol +butanol - SEV - 
6 1:0.7 1,4 dioxane +methanol - SEV - 
7 1:0.7 None 30 Dry grinding - 
8 1:0.7 Methanol 30 SAG - 
9 1:0.7 Water 30 SAG - 
10 1:0.7 Acetone 30 SAG - 
11 1:0.7 Ethyl acetate+ methanol - SEV - 
12 1:0.7 Propanol + methanol - SEV - 
13 1:0.7 1,4-dioxane + methanol - SEV - 
14 1:0.7 None 30 Dry grinding - 
15 1:0.7 Methanol 30 SAG - 
16 1:0.7 Acetone 30 SAG - 
17 1:0.7 Ethyl acetate+methanol - SEV - 
18 1:1 None 30 Dry grinding Positive 
19 1:1 Water 30 SAG Negative 
20 1:0.5 None 30 Dry grinding - 
21 1:1 Acetone 30 SAG Positive 
22 1:1 Methanol 30 SAG Negative 
23 1:0.7 NaOH 30 SAG - 
24 1:0.5 NaOH 30 SAG - 
25 1:1 HCL 30 SAG - 
26 1:0.5 HCL 30 SAG - 
27 1:1 Ethanol 30 SAG - 
28 1:1 Acetone/chloroform - VD - 
29 1:0.5 Acetone/chloroform - VD - 
30 1:0.5 Water 30 SAG - 
31 1:1 Phosphate buffer - SEV - 
32 1:0.5 Phosphate buffer - SEV - 
33 1:1 Phosphate buffer 30 SAG - 
34 1:1 Phosphate buffer+NaOH - SEV - 
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Amoxicillin tri-hydrate with succinic acid 
Sample Ratio Solvent Time/
min. 
Method Result 
1 1:0.7 Water 30 SAG Negative 
2 1:0.7 Acetone 30 SAG - 
3 1:0.7 Ethyl acetate+ methanol - SEV - 
4 1:0.7 Propanol + methanol - SEV - 
5 1:0.7 1,4 dioxane + methanol - SEV - 
6 1:0.7 None 30 Dry 
grinding 
Positive 
7 1:0.7 Methanol 30 SAG Negative 
8 1:0.7 Acetone 30 SAG - 
9 1:0.7 Ethyl acetate+methanol - SEV - 
10 1:1 Water+methanol - SEV - 
11 1:1 NaOH - SEV - 
12 1:1 HCL solution+acetone - SEV - 
13 1:1 NaOH solution 30 SAG - 
14 1:0.5 NaOH solution 30 SAG - 
15 1:1 HCL solution 30 SAG - 
16 1:1 DMSO - SEV - 
17 1:1 DMSO - SEV - 
18 1:0.5 DMSO - SEV - 
19 1:1 Water 30 SAG - 
20 1:0.5 NaOH solution - SEV - 
21 1:1 NaOH solution - SEV - 
22 1:0.5 NaOH solution 30 Heating - 
23 1:1 NaOH solution 30 Heating - 
24 1:1 None 30 Dry 
grinding 
Positive 
25 1:1 Acetone/chloroform - VD - 
26 1:0.5 Acetone/chloroform - VD - 
27 1:1 Acetone 30 heating - 
28 1:0.5 Acetone 30 heating - 
29 1:1 Methanol 30 heating - 
30 1:0.7 Methanol 30 heating - 
31 1:1 HCL  30 heating - 
32 1:0.5 HCL 30 heating - 
33 1:0.7 Methanol 30 SAG - 
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Amoxicillin tri-hydrate with cinnamic acid 
Sample Ratio Solvent Time/min. Method Result 
1 1:0.5 None 30 Dry 
grinding 
Negative 
2 1:1 None 30 Dry 
grinding 
- 
3 1:1 Methanol - SEV - 
4 1:0.5 Methanol - SEV - 
5 1:1 DMSO - SEV - 
6 1:0.5 DMSO - SEV - 
7 1:0.5 Water 30 SAG - 
8 1:1 Methanol 30 SAG - 
9 1:0.5 Methanol 30 SAG - 
10 1:0.5 NaOH solution - SEV - 
11 1:1 NaOH solution 30 SEV - 
12 1:0.5 NaOH solution 30 Heating - 
13 1:1 NaOH solution 30 Heating - 
14 1:1 HCL +NaOH solution - SEV - 
15 1:1 Methanol/chloroform - VD - 
16 1:0.5 Methanol/chloroform - VD - 
17 1:1 Methanol/chloroform - VD - 
18 1:1 Water|+methanol - SEV - 
19 1:1 NaOH - SEV - 
20 1:1 HCL solution+acetone - SEV - 
21 1:1 NaOH solution 30 SAG - 
22 1:1 Phosphate buffer - SEV - 
23 1:0.5 Phosphate buffer 30 SAG - 
24 1:1 Phosphate buffer 30 Heating  
25 1:0.7 Acetone +water - SEV - 
26 1:1 Acetone +NaOH - SEV - 
27 1:1 Acetone+ HCL solution - SEV - 
28 1:2 Acetone 30 SAG - 
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Appendix B 
FTIR spectra and DSC thermogram of amoxicillin tri-hydrate and 
fourteen co-formers 
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FTIR Spectra 
1. Amoxicillin tri-hydrate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
55.6
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96.2
cm-1
%T 
2969.92
1772.26
1684.81
1615.28
1576.40
1519.29
1481.52
1450.62
1396.00
1378.30
1361.21
1328.00
1312.64
1282.43
1217.80
1196.22
1177.72
1144.28
1119.93
1076.63
1021.01
1002.67
986.18
922.37
872.94
847.67
837.79
732.85
695.33
3158.73
3452.38
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2. Saccharin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
34.2
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96.0
cm-1
%T 
3093.82
2948.00
2694.01
1864.75
1715.29
1592.89 1458.17
1296.57
1256.87
1174.22
1160.49
1138.43
1118.58
1054.76
1013.54
972.65
897.96
794.82
774.17
757.15
700.88
3400.79
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3. Oxalic acid dehydrate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
51.0
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98.6
cm-1
%T 
3415.25
1437.16
1113.69
719.20
1613.43
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4. L, D-tartaric acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
48.8
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98.8
cm-1
%T 
3399.56
3328.22
3096.81
1715.85
1445.47
1396.31
1363.30
1318.51
1252.56
1218.28
1185.71
1127.65
991.98
939.34
871.87
828.62
788.45
733.58
661.94
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5. Salicylic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
45.8
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
95.8
cm-1
%T 
3231.62
2851.58 2591.24
1654.88
1609.43
1579.23
1481.75
1464.77
1441.21
1382.82
1324.05
1291.01
1243.04
1207.72
1153.56
1089.18
1030.21
964.32
887.27
867.19
852.08
783.87
690.51
657.81
3003.96
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6. Citric acid monohydrate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 600 515.0
37.9
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
99.1
cm-1
%T 
3295.55
2957.20
2544.25
1752.66
1721.69
1684.13
1417.77
1390.67
1317.09
1290.41
1254.20
1169.71
1103.75
1052.74
1018.71 897.88
824.12
778.80
718.16
665.23
596.61
548.04
522.66
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7. Maleic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
27.9
30
35
40
45
50
55
60
65
70
75
80
85
90
95
96.9
cm-1
%T 
3057.94
2870.85
2684.90
2605.08
2505.69
2378.10
2162.17
1887.77
1703.85
1632.98
1584.52
1563.50
1458.11
1429.49 1259.78
1218.50
985.31
914.27
785.45
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8. Succinic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
57.6
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98.6
cm-1
%T 
2929.76
2625.89
2532.40
1680.31 1409.20
1305.32
1196.18
1175.58 800.17
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9. Cinnamic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
38.4
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92.9
cm-1
%T 
2828.86
2542.75
1671.37
1627.56
1577.73
1495.21
1448.85
1418.09
1333.02
1311.47
1283.33
1220.34
1206.16
1176.64
1098.55
1073.81
1026.42
1000.64
977.15
942.89
911.16
874.95
845.90
766.81
708.61
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10. Stearic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
37.0
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98
99.7
cm-1
%T 
2955.56
2848.29 1698.37
1471.76
1463.67
1430.04
1411.24
1348.12
1330.75
1310.79
1295.70
1259.18
1249.26
1226.94
1206.59
1187.52
1099.44
938.31
782.09
727.45
720.34
687.94
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11. L-aspartic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
54.0
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
97.8
cm-1
%T 
2951.16
1879.98
1684.66
1641.24
1599.50
1501.76
1419.72
1357.56
1289.75
1149.23
1118.71
1033.61
988.95
935.99
898.28
872.92
777.19
752.57
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12. Nicotinamide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
29.6
35
40
45
50
55
60
65
70
75
80
85
90
94.8
cm-1
%T 
3357.30
3149.40
2786.35
1673.74
1614.70
1593.00
1574.86
1485.90
1421.73
1339.82
1231.38
1202.07
1153.89
1124.59
1091.59
1028.58
969.41
936.00
828.17
776.84
700.80
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13. Benzoic anhydride 
 
 
 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
19.1
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
96.4
cm-1
%T 
3063.48
2556.33
1920.31
1773.13
1713.31
1686.02
1598.00
1584.84
1490.88
1450.71
1423.54
1321.34
1283.33
1208.09
1169.57
1073.34
1032.09
1011.54
993.05
939.20
874.56
803.63
779.60
683.17
667.10
1827.53
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DSC thermograms 
 
 
1. Amoxicillin tri-hydrate 
 
 
 
 
2. Saccharin 
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3. Oxalic acid dehydrate 
 
 
 
 
 
 
4. L, D-tartaric acid 
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5. Salicylic acid 
 
 
 
 
 
6. Citric acid monohydrate 
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7. Maleic acid 
 
 
 
 
 
 
8. Succinic acid 
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9. Cinnnamic acid 
 
 
 
 
 
10. L-aspartic acid 
 
11. Nicotinamide 
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12. Benzoic anhydride 
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APPENDIX C 
H1-NMR SPECTRA  
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1. Amoxicillin tri-hydrate 
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2. Saccharin 
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3. Oxalic acid dehydrate 
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4. D-tartaric acid 
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5. Nicotinamide 
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6. Salicylicacid 
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7. Succinic acid 
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8. Benzoic anhydride 
 
 
 
 
 
 
 
179 
 
 
9. L-tartaric acid 
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10. AMS1 
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11. AMS2 
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12. AMO 
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13. AMDT 
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14. AMN 
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15. AMSL 
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16. AMSC 
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17. AMB 
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18. AMP 
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